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ABSTRACT
Ocular infection with herpes simplex virus 1 (HSV-1) can result in a chronic
immunoinflammatory stromal keratitis (SK) lesion that is a significant cause of human
blindness. These lesions are mainly orchestrated by IFN-gamma producing CD4+ T cells (Th1)
and neutrophils. HSV being neurotropic in nature can also disseminate into the brain and lead to
herpes simplex encephalitis (HSE). In this study we investigated the role of miR-155 in the
pathogenesis of HSK and HSE.
The first part of the dissertation (I) reviews literature regarding the contribution of
miRNAs in innate and adaptive immune responses. It also focuses on their involvement in
neuroinflammation during inflammatory and viral diseases.
In the second part (II) we investigated the role of miR-155 in HSV-1 latency and HSE.
We observed that miR-155-/- (microRNA-155 knockout) mice are highly susceptible to HSE and
zosteriform lesions. These miR-155-/- animals also show increased viral reactivation from
latency when compared to the control WT (wild type) animals. One explanation for these
observations was diminished CD8 T cell effector responses in miR-155-/- animals.
In the third part (III) we evaluate the role of miR-155 in the pathogenesis of SK. Our
results showed that miR-155 expression is increased in corneas after HSV-1 infection and
suppression of miR-155 production resulted in milder lesions that was associated with
diminished Th1 and Th17 responses as well as reduced inflammatory cytokine production.
Collectively, these studies identified a novel role for miR-155 in regulating HSE and
promoting inflammation during HSK.
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Chapter 1
BACKGROUND AND OVERVIEW
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Herpes Simplex Virus-1 infection
Herpes Simplex Virus-1 (HSV-1) is a pathogen in all human societies with up to 70-80%
prevalence in some adult populations (1). The transmission of HSV occurs via contact with
secretions, skin and mucosal membranes from symptomatic or asymptomatic individuals that
shed virus (2). HSV-1 mostly affects the face and other mucosal sites, although in some
communities the genital mucosa, the usual site of infection for HSV-2, can be affected (3). HSV1 initially replicates in the epithelial layer, and then via retrograde transport, establishes latency
in the trigeminal ganglia (TG). During latency the virus does not replicate, however, immune
suppression and several stress related events in the host could result in reactivation of the virus
from latently infected TG (4). After reactivation, the virus can migrate to the initial site of
infection and can cause inflammatory reactions in that site which in some cases can be the eye
and the brain (5, 6).
When the virus enters the cornea, a chronic vision impairing immunoinflammatory
condition may result, which is termed herpetic stromal keratitis (HSK) (7). When virus enters the
brain it causes acute inflammation and significant pathological damage which gives rise to
herpes simplex encephalitis (HSE) (8). If untreated, HSK leads to blindness and HSE mediated
damage leads to nearly 70% lethality (8). The role of microRNAs (miRNAs) in both HSK and
HSE is new field and has just started to be explored.

Biogenesis of miRNAs
The canonical process of miRNA biogenesis begins in the nucleus where the enzyme
Drosha and its partner protein DGCR8 process the nuclear pri-miRNA into a ~ 70 nucleotide
	
  

2	
  

precursor miRNA (pre-miRNA). The pre-miRNA is then exported from the nucleus to the
cytoplasm with the help of Exportin-5/RanGTP (GTP-binding nuclear protein Ran), which
specifically recognizes the structure of pre-miRNA molecules. In the cytoplasm, an enzyme dicer
digests the pre-miRNA into a 21–25 nucleotide miRNA duplex. After this step the miRNA
duplex is loaded into the miRNA-induced silencing complex (miRISC) that also contains
argonaute proteins where the sense strand is degraded. miRNA antisense strand guides miRISC
to its target mRNA resulting in target mRNA degradation or translational repression. (Please see
figure 1). Accordingly, if the miRNA has a complete complementary sequence to the target
mRNA, it degrades target mRNA with the help of argonaut proteins. If the miRNA has partial
complementarity to the target mRNA, translational repression results via different mechanisms
including co-translational protein degradation, inhibition of translational elongation, premature
termination of translation, and inhibition of translation initiation (9). Although, most miRNAs
are generated as described above, there are some exceptions, which could use a different
pathway such as mirtrons, which resemble pre-miRNA hairpins, bypassing the need for Drosha,
and only require Dicer for maturation. This has been reviewed in detail by others (10).

miR-155 and inflammation
miRNA-155 is one of the most studied miRNA with respect to both innate and acquired
immune responses.

miR-155 expression is expressed at low levels in monocytes and

macrophages, however the level increases soon after toll like receptor (TLR)-2,3,4 and 9
stimulation during both bacterial and viral infections (11). Moreover, cytokines such as Tumor
necrosis factor (TNF) and interferon’s (IFNs) also induce expression of miR-155 in macrophages
(11, 12). Various studies have shown that transient increase in miR-155 after TLR stimulation
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mediated by TNF receptor associated factor 6 (TRAF-6), activator protein 1 (AP-1), c-Jun Nterminal kinase (JNK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) transcription factors and leads to granulocyte/monocyte expansion. Apart from its role in
differentiation, Rodriguez, A. et al

have shown that miR-155 is also essential for antigen

presentation where the loss of miRNA-155 impaired the ability of myeloid dendritic cells (DCs)
to present antigen and trigger T cell activation (13). Moreover, miRNA-155 positively regulates
the development, apoptosis and interleukin-12 (IL-12) production in human DCs (14). miRNA155 also promotes autophagy, phagocytosis, endocytosis and cytokine secretion in macrophages
by targeting its negative regulators such as Ras homolog enriched in brain (Rheb) and
Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 (SHIP-1) (11, 15, 16). While over
expression of miR-155 leads to Acute Myeloid Leukemia (AML) in certain cases, blocking its
induction by antagomirs have shown to repress the production of pro-inflammatory cytokines,
phagosome maturation and macrophage survival (17). Also, reduction in miRNA-155 promoted
M2 macrophages by directly upregulating its target CCAAT/enhancer-binding protein beta
(C/EBPβ) and Arginase-1 expression (18).
In terms of adaptive immunity miR-155 has been shown to have a critical role in T cells.
miR-155 is expressed by both activated CD4 and CD8 T cells and T cell receptor (TCR)
engagement has been shown to induce upregulation of this miRNA (19, 20). TCR signaling
cascade activates nuclear factor of activated T cells (NFAT) and NF-κB, both of which induce
the upregulation of miR-155 expression. microRNA-155 knockout (miR-155KO) T cells show a
type 2 helper cells (Th2) bias under neutral conditions with more CD4 T cells producing IL-4
than IFN-γ. This bias was reflected by increased levels of c-maf (miR-155 target), which is
important for the production of IL-4 (13). Animals deficient in miR-155 because of gene
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knockout (KO) are resistant to the induction of some autoimmune diseases such as experimental
autoimmune encephalomyelitis (EAE), colitis and collagen induced arthritis (21-23).
Additionally, in humans high levels of mir-155 have been associated with several autoimmune
diseases which include multiple sclerosis (MS), rheumatoid arthritis (RA), and atopic dermatitis
(24-26). The resistance of miR-155KO mice to autoimmune diseases was contributed in part due
to defective Type 1 helper cells (Th1) and T helper 17 cells (Th17) cell responses. miR-155
targets Ship1 and Interferon receptor α (IFN-yRa) in CD4 T cells and promotes Th1 cell
differentiation (20). miR-155 promotes Th17 cell responses by targeting Ets-1 which is a
negative regulator of Th17 differentiation (27). Additionally, miR-155KO Th17 cells show
reduced expression of IL-23 resulting in these cells being hypo responsive to IL-23 signaling
(27). miR-155 is also expressed by regulatory T cells (Tregs) and regulates Treg homeostasis in a
competitive setting. In fact forkhead box P3 (Foxp3) the major transcription factor for Tregs has
been shown to regulate mir-155 expression in Tregs. miR-155 targets Suppressor of cytokine
signaling 1 (SOCS1) and thus miR-155KO Tregs have increased SOCS1 mRNA levels.
Increased SOCS1 levels results in reduced signal transducer and activator of transcription 5
(STAT5) phosphorylation, downstream of interlukin-12 receptor (IL-2R) signaling and a wellestablished role of IL-2 signaling in the survival of Treg cells has been established suggesting
that defective IL-2 signaling could be responsible for defective Treg homeostasis (28).
Additionally, miR-155KO Tregs showed reduced proliferative activity in a competitive
environment, which could also in part explain defective Treg homeostasis. Some reports also
suggest defective T follicular helper cell differentiation in miR-155KO animals following
immunization, viral infection, or during age-related inflammatory disease. This was attributed to
increased levels of miR-155 targets FOS-like antigen 2 (Fosl2) and pellino E3 ubiquitin protein
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ligase 1 (Peli 1). Fosl2 is a repressor of T follicular helper cell (Tfh) development and Peli 1
inhibits NFκB activation, which is required for the induction of Tfh cell associated genes. These
defective Tfh cell responses in turn lead to defective humoral immune response and reduced
germinal center (GC) formation (29). Another report by Rodriguez et al. showed that miR155KO mice have defective GC formation and fail to produce high-affinity IgG1 antibodies to
thymus dependent and independent antigens and this was attributed to a B cell intrinsic defect
(13). miR-155 targeting PU.1 in B cells leads to increased B cell maturation and IgG1 classswitched differentiation (13). Cytotoxic CD8 T cell function is also shown to be regulated by
miR-155 (19, 30-32). The effector CD8 T cell responses to virus and bacterial infections and in
cancer depend on miR-155 (30, 31). The reduced AKT (also known as protein kinase B)
phosphorylation by miR-155 was observed after L. monocytogenes infection (31). Moreover,
components associated with IFN signaling were also found to be increased in miR-155KO CD8
T cells (19). In conclusion, miR-155 impacts various aspects of immunity and likely to be a good
therapeutic target against human autoimmune and inflammatory diseases.

miRNAs and Herpes Stromal Keratitis
Innate immunity
HSV infection of the corneal epithelial cells leads to induction of innate immune
responses. HSV sensors include TLR 2, 3, and 9 and some other such as retinoic acid-inducible
gene 1 (RIG 1) and inflammasomes (33-35). Ligation of TLR’s causes activation of the NFkB
pathway, which leads to the production of several pro-inflammatory cytokines, chemokines,
interferons and angiogenic factors that are involved in the pathogenesis of HSK (33, 35). TLR 2
and 9 ligation has been shown to be critical in HSK as mice lacking TLR2, TLR 9 or myeloid
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differentiation primary response 88 (MYD88) lead to reduced HSK lesions and neovascularization (36). It is suggested that TLR ligand activity of HSV may be a major mechanism
by which the virus induces early events necessary for the development of the inflammatory
disease. These include the induction of cytokines such as IL-6, IL-1β, and TNF-α, the
chemokines macrophage inflammatory protein (MIP)-1 alpha (MIP-1α) and MIP-2, enzymes
such as cyclooxygenase-2 (COX-2), associated with the production of inflammatory molecules,
and molecules responsible for neovascularization of the usually avascular eye, such as vascular
endothelial growth factor (VEGF) and matrix metallopeptidase 9 (MMP9) (33) . The
accumulating evidence shows that TLR function is subject to regulation by numerous miRNA
species (37). It is of interest to note that that these miRNAs do not directly target the TLR’s but
instead target molecules that are required for the TLR signaling cascade such as MyD88,
interleukin-1 receptor-associated kinase (IRAK), TRAF6, and IκB kinase (IKK) (37). Moreover,
TLR induced transcriptional factors are also subject to miRNA regulation. Thus miRNAs that
either targets the TLR cascade or the cytokines produced during the innate phase might be of
interest. However, what role if any these aforementioned miRNAs such as miR-146a, miR-155
and miR-21 (discussed below) play during the innate phase of HSK pathogenesis remains to be
seen.
Innate immune cells such as DCs, natural killer (NK) cells, γδ-T cells, neutrophils and
macrophages participate in viral clearance and the subsequent ocular inflammation by secreting
various effector molecules such as type I interferons, cytokines and chemokines (IL-17, IL-1β,
IL-12, MIP-2, TNF-α, IFN-γ, IL-23) (33). The function of all of these cell types is influenced by
miRNA expression (38-41). For example miR-146a, miR-155, miR-21, miR-147 and miR125b regulate the function of macrophages (42, 43). miR-223 has been shown to regulate the
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migration, proliferation an activation of neutrophils (41, 44). Also, miRNAs such as miR-21,
miR-155, miR-221 and miR-146a control DC function, differentiation and activation (40).
Similarly, NK cell cytokine production can be regulated by miR-150, miR-155, miR-29, and
miR-15/16 while the production of cytotoxic molecules such as granzyme B and perforin can be
regulated by miR-223, miR-378, miR-30e, and miR-27a* (38). It is becoming evident that
several miRNAs can play a critical role during the innate phase of an inflammatory response and
it could be the magnitude and balance of this innate response is regulated by miRNAs. This also
sets the stage for an adaptive immune response, which in some cases might lead to pathogen
clearance, while in others leads to immunopathology as is the outcome in HSK.

Adaptive immunity
The HSK pathogenesis is very complex, but it is mainly thought to be a T cell
inflammatory reaction. Studies in animal models have revealed that these HSK lesions are
orchestrated mainly by IFN-γ–producing CD4+ T cells (Th1) and, to a lesser extent, by IL-17–
producing CD4+ T cells (Th17) (45, 46). Stromal lesions do not occur in animals that lack T
cells, but lesions can be restored with adoptive transfer of CD4+ T cells (33). The ocular lesion
severity is controlled by Tregs as removing or expanding Tregs from the onset of lesion
induction results in exacerbated or diminished lesions, respectively (33). Multiple miRNAs are in
involved in the activation, differentiation, effector function and recruitment of both effector CD4
T cells and Tregs (47). However, we mention only relevant miRNAs that could be involved in
the pathogenesis of HSK and hence might be used as a good therapeutic target.
One report by our lab has already shown the involvement of one such miRNAs, miR-155
in T cell biology and in the pathogenesis of HSK lesions. miR-155 is a proinflammatory miRNA
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which is required for normal immune function (48). The increased ocular expression of miR-155
was associated with Th-1 and Th-17 cell responses, and reduced levels of miR-155 targets IFNγRα and Ship1, which are required for T cell differentiation and function. miR-155KO mice
were resistant to developing HSK. We were also able to show that anti-155 sequences given in
the form of antagomir nanoparticles provided resistance against HSK in WT mice. Thus
manipulating miRNAs show promise and could be used to target other miRNAs that are involved
in inflammatory or resolution components of HSK. One such miRNA is miR-146a which is
expressed in Tregs and conventional T cells, and its absence leads to elevated expression of one
of its targets, STAT1, and an unchecked Th1 response (49). miR-146a also regulates NF-κB
activity, at least partly through repressing the NF-κB signaling transducers TRAF6 and IRAK1
(50). It will be interesting to evaluate the contribution of miR-146a in the pathogenesis of HSK;
we expect rapid onset of HSK and severe ocular lesions in mice lacking miR-146a. Another
miRNA that regulates Th1 responses is miR-29 which targets T-box transcription factor TBX21
(Tbet) and Eomesodermin (Eomes) transcription factors and suppresses IFN-γ production
(51). The proliferative response of Th-1 cells and IFN-γ production are also controlled by a
species of miRNA, miR-17-92. The mice lacking miR-17-92 demonstrated attenuated delayed
hypersensitivity response and reduced tumor rejection (52). Thus it would be of interest to see if
any of these miRNAs play a role during the pathogenesis of HSK. Other miRNAs that might
influence the pathogenesis of HSK are those that regulate Th17 differentiation or the production
of IL-17A. IL-17A was shown to have a pathogenic role in the progression of HSK.
Accordingly, miR-21, miR-155 miR-301a, and miR-326 were shown to promote Th17
differentiation (53-55). Therefore blunting the expression of these miRNAs might reduce IL17A, which might lead to diminished HSK lesions. This merits further investigation.
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Treg function is also subject to modulation by species of miRNAs. The most studied
miRNAs are miR-146a, miR-17-92, miR-10a and miR-155. Deficiency of miR-146a in Tregs
leads to fatal Th1 cell mediated pathology, a phenotype previously observed with mice in which
Treg cells lack the miRNA generating machinery (Dicer/Drosha) (49). These experiments were
performed using bone marrow chimeras so the contribution of miR-146a in impacting myeloid
cells cannot be nullified (49). The intrinsic role of miR-146a in Tregs remains to be verified
using conditional mutant mice. Another well-studied miRNA in Tregs is miR-17-92 cluster (56).
This cluster influences IL-10 production in Tregs as mice deficient in miR-17-92 developed
severe EAE lesions. Tregs function can be regulated at the epigenetic level thus restraining Treg
plasticity into effector T cells. One such miRNA is miR-10a that stabilizes the Treg phenotype
by maintaining stable FoxP3 expression (57). miR-10a also restrains Treg transition into TFH
cells as well as it shows inhibitory effect on Th-17 cells (58). Similarly, another miRNA, miR155 is required to provide competitive fitness to Tregs (28). Consequently, miR-155 deficient
mice show reduced Treg numbers in peripheral organs (28). Finally, Tregs were shown to
transfer miRNAs in exosomes to effector T cells leading to suppression. Treg exosomes revealed
a critical miRNA, Let-7d in this process (59). Although, several aspects such as how Treg
suppression is regulated by miRNAs, or miRNA signature between natural Treg (nTreg) and
induced Treg (iTreg), details as to how miRNAs contribute to Treg plasticity needs to be worked
out.

miRNAs and Herpes Simplex Encephalitis
HSE is an infection of the brain by herpes virus. It affects 1 in 500,000 individuals every
year. The majority of the cases result from virus reactivation in the peripheral ganglion and in the
small number of individuals with mutations in toll like receptor 3, HSE is a common problem
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(60). Treatment includes high doses of intravenous acyclovir or other antivirals, but 20% of the
affected patients are left with neurological sequelae. The underlying processes that drive HSE
seem to involve both direct insult by the virus as well as bystander damage by a host response to
the virus. It is conceivable that miRNAs expressed by the cells of the CNS or the immune system
could influence the susceptibility of these cells to viral infection and also contribute to the
inflammation thus leading to encephalitis. Currently the involvement of miRNAs in HSE is still
in its infancy and needs to be further investigated.

Microglia
Microglial cells make up the first line of defense against virus infection and are the
resident macrophages of the central nervous system (CNS) (61). Microglia do not originate from
the same precursor cells as the astrocytes, oligodendrocytes, or neurons but are instead derived
from myeloid progenitor cells and share several characteristics with monocytes, macrophages
and dendritic cells. Similar to macrophages, microglia can express essentially all of the many
TLR family members (61). HSV has the ability to trigger TLRs in microglia and is associated
with production of considerable amounts of ROS, TNF-α, IL-1β, CXCL10/IP-10, and
CCL5/RANTES, together with smaller amounts of IL-6, CXCL8/IL-8, and CCL3/MIP-1α, in
response to nonproductive infection (62). While these cytokines and chemokines might be
beneficial to clearing invading pathogens, they can also cause irreparable harm through
bystander damage to crucial host cells particularly neurons. Whether miRNA are involved in
driving such harmful processes after HSV infection as would seem likely merit further
investigation.
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One such miRNA influencing microglial function is miR-124 (63). One group showed
that miR-124 is required to keep the microglia in a resting state in EAE, the mouse model for MS
(63). miR-124 is highly expressed in resting microglia but upon activation of these microglia,
miR-124 expression goes down. During the resting state miR-124 directly inhibits the expression
of the transcription factor CEBPα that results in down regulation of PU.1 expression. PU.1 is a
master regulator of macrophage cell differentiation, and proliferation and it plays a critical role
in activation of macrophages (64, 65). Thus, when miR-124 is downregulated during EAE it
increases the expression of PU.1, which promotes microglia activation, proliferation and
differentiation thereby contributing to neuroinflammation. After HSV-1 infection of the brain,
microglial cells express increased MHC Class 1 and class II glycoproteins and show an activated
phenotype (66). Thus it will be of interest to see if miR-24 is upregulated in microglia after HSV
-1 infection and if providing antagomir-124 after HSV-1 infection would dampen the
proinflammatry milieu generated as a consequence of activated microglia. Moreover the outcome
of miR-124 on the severity of HSE marks investigation.
Another miRNA that has received interest is miR-181c, which is downregulated in
microglia after oxygen-glucose deprivation (67). This miRNA seems to regulate TNF-α
production from microglia, as it could directly target TNF-α mRNA (67). Downregulation of this
miRNA after oxygen-glucose deprivation leads to increased levels of TNF-α, which results in
neuronal apoptosis (67). TNF-α inhibits HSV replication in astrocytes, and in addition TNF-α
knockout mice are much more susceptible to HSE (68, 69). Thus TNF-α seems to have a
protective role in HSE and it is conceivable that provision of antagomir-181c to mice might
provide protection against HSE by increasing the production of TNF-α.

	
  

12	
  

miR-155 was previously shown to be upregulated in microglial cells after stimulation
with LPS as well as after Japanese encephalitis virus challenge (70, 71). In both cases, miR-155
targeted anti-inflammatory proteins in the microglia namely SOCS1 and Ship1 which led in turn
to the upregulation of several inflammatory mediators. The finding reported in this thesis support
the role of miR-155 in inflammation, which was associated with proinflammatory Th1 and Th17
cell responses. However, its role in microglia after HSV infection remains to be seen. There are
some contradictory reports on the anti viral role of miR-155 in microglia after Japanese
encephalitis virus infection. One report suggests that JEV infection of microglia cell line that is
over expressing miR-155 causes decreased production of IFN-β probably due to miR-155
targeting IRF8 a molecule required for the production of type 1 interferons (71). However the
other report suggests that miR-155 induction after JEV infection increased IFN-β and
proinflammatory cytokine production that was reflected by miR-155 targeting Ship1 (70). This
decrease in Ship 1 results in hyperphosphorylation of Serine/threonine-protein kinase TBK1
(TBK-1) and subsequent phosphorylation of Interferon regulatory factor (IRF)3/7 and NF-κB,
resulting in augmented IFN-β production and induction of proinflammatory cytokines. The
difference in these two reports could be due to different cell lines used in vitro. It would
therefore be interesting to analyze the effects of HSV infection on miR-155 sufficient and
deficient microglial cells and its association to CNS infection by HSV.

Astrocytes
Astrocytes, together with microglia and macrophages, participate in innate inflammatory
responses in the CNS (72). Just like microglia, murine astrocytes also express a wide variety of
TLRs, albeit at lower levels (73). Moreover, interferon production by astrocytes is considered to
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be a crucial CNS defense mechanism against various invading pathogens (74-76). For example
in the case of HSV-2, HSV triggering of TLR-3 in murine astrocytes leads to the production of
IFN-β, which in turn provides protection against HSE. This is also true for humans, as patients
with mutation in the TLR-3 gene were shown to be highly susceptible to HSE (60, 77).
Additionally, astrocytes can produce TNF-α and IL-6 in a TLR-3 dependent manner, which were
shown to have antiviral functions. It is thus conceivable that dysregulation of miRNAs after
HSV-1 infection of the astrocytes could contribute to the increased susceptibility of these cells to
HSV-1 infection. This area has received minimum attention and needs to be further investigated.
One study by Iyer et al. reported a role of miR-146a in astrocyte mediated inflammatory
responses (78). They showed that miR-146a was upregulated upon exposure of human astrocytes
to IL-1β or LPS. This miRNA downregulated the expression levels of IRAK-1, IRAK-2 and
TRAF-6 mRNA, all of which could eventually lead to the induction of proinflammatory
cytokines such as IL-6 and TNF-α as well as antiviral type 1 interferon production (50, 79). It is
well known that TNF-α, IL-6 and IFN-β have antiviral roles in HSE (62). Thus it would of
interest to see if miR-146a is dysregulated during HSE and if providing antagomir-146a
nanoparticles might provide protection against HSE. This aspect merits investigation.
A recent study has also evaluated the role of miR-21 and miR-145 in astrocytes after
spinal cord injury (SCI). Bhalal et al. report that miR-21 is upregulated after SCI and using
transgenic mice that overexpress miR-21 specifically in astrocytes showed that miR-21
attenuates hypertrophic reactive responses of astrocytes to injury (80). Wang et al. showed that
miR-145 is downregulated in both astrocytes and neurons after SCI and this down regulation is
associated with astrogliosis and formation of glial scarring (81). They suggest that miR-145
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targeting of c-Myc and GFAP could be an explanation for the astrogliosis after SC1. These two
miRNAs might also play a role in HSE and this possibility needs to be investigated.
Lastly a proinflammatory function of miR-155 has been linked to human astrocytes. miR155 was induced by TLR-3 ligation and by various cytokines such as IL-1β and TNF-α (82).
miR-155 upregulation leads to decreased levels of its target SOCS1. Lower levels of SOCS1
leads to increased production of pro-inflammatory cytokines IL-6, TNF-α and IL-8. In the
studies reported in this thesis, we find that miR-155KO mice are more susceptible to HSE. Since
miR-155 is playing a pro-inflammatory role in astrocytes it is unlikely that miR-155KO mice are
dying from inflammation, rather it is conceivable that the anti-viral role of some of these
cytokines might be defective which leads to excessive viral replication. This area is being further
analyzed.

Neurons
Neurons employ various strategies to counteract viral infection. Such strategies include
production of interferons, and induction of autophagy, which operate in parallel to defend against
HSV-1 infection (83). Genetic ablation or viral inhibition of host autophagy results in
significantly higher levels of HSV-1 replication in neuronal cells (83). It is well known that
multiple miRNAs play roles in cell autophagy. In fact miR-155 was shown to positively regulate
autophagy (15). Forced expression of miR-155 in mycobacterial infected macrophages led to
accelerated autophagic response and decreased survival rate of intracellular mycobacteria (15). It
is therefore conceivable that increased expression of miR-155 in neurons after HSV infection
may lead to an increased autophagic response, which in turn could counteract HSV infection of
the neurons. As mentioned before, miR-155KO mice are more susceptible to HSE. It is therefore
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possible that miR-155 deficiency in neurons could lead to a diminished autophagic response and
hence increased virus susceptibility. This area is currently under investigation in our laboratory.
Another recent study illustrates the role of neurons in antiviral defense. Accordingly a
study by Pan et al. found that neurons express miR-138, which targets ICP0, a viral
transactivator of lytic gene expression and promotes host survival and viral latency. They
showed that a mutant HSV-1 (M138) with disrupted miR-138 target sites in ICP0 mRNA
exhibits enhanced expression of ICP0. Moreover lytic transcripts in TG during the establishment
of latency resulted in increased mortality and encephalitis symptoms (84). Thus although the
neuronal miRNAs did not seem to directly influence the neuroinflammation they indirectly could
lead to exacerbated immune responses or viral growth thus resulting in neuroinflammation.

miRNAs and antiviral immunity
Host miRNAs regulating viral and cellular genes
Several groups have reported changes in the cellular miRNA expression profile following
viral infection (37). There could be two scenarios when it comes to host miRNAs regulating
antiviral immunity. Accordingly, host miRNAs could target host cell genes with the outcome
being greater susceptibility or resistance. The other situation, which is being explored, is the
possibility of host miRNAs targeting viral genes and regulating antiviral immunity.
A report by Jopling et al. revealed that hepatitis C virus (HCV) viral replication increases
as a consequence of changes in host miRNA (85). These studies showed that liver specific
cellular miR-122 enhanced HCV virion production. Interestingly, miR-122 exerts this pro-viral
activity in an unconventional manner. miR-122 binds to two sites near the 5' end of HCV
genomic RNA and interferes with the recognition by the innate immune system (85).
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Pharmacological inhibition of miR-122 led to significant control of HCV in the blood and liver
of infected chimpanzees (86). Another recent report by Zhao et al. showed that hepatitis B virus
(HBV) infection down-regulated miR-26b levels in human liver cells and that miR-26b targeted
cysteine and histidine rich domain containing 1 (CHORDC1), which is involved in regulating
HBV transcription and replication (87). Thus down regulation of miR-26b, as a consequence of
HBV infection, helped to increase viral replication and transcription (87). It was also noted
during Epstein–Barr virus (EBV) latency, that viral protein latent membrane protein 1 (LMP1)
activated the miR-146a promoter leading to miR-146 induction. The miR-146a then attenuated
expression of several interferon responsive genes (88). Moreover, LMP1 also induced miR-29b,
which reduced expression of T cell leukemia protein that is involved in cell survival and
proliferation (89).
miRNA modulation of viral tropism is supported by another recent report (90). In this
study, Trobaugh et al show that miR-142-3p is expressed by the cells of the myeloid-lineage
(90). miR-142-3p limited replication of North American Eastern Equine Encephalitis virus
(EEEV) by binding to the sites of 3' non translated regions of viral RNA. However, restriction of
myeloid cell tropism and subsequent reduction in innate immune response promoted
neurological manifestations, which are characteristics of EEEV infection in humans (90).
Host miRNAs are not always beneficial for the virus but can also inhibit viral replication.
Accordingly, a recent report demonstrated that IFN-β, an antiviral cytokine, induces numerous
cellular miRNAs (such as miR-196, miR-296, miR-351, miR-431 and miR-448), with sequencepredicted targets within the HCV genomic RNA (91). Overexpression of these miRNAs in
infected liver cells substantially attenuated viral replication demonstrating the importance of
miRNAs in anti-viral immunity. In another study, cellular miRNAs such as miR-28, miR-125b,
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miR-150, miR-223 and miR-382 were shown to restrict human immunodeficiency virus (HIV)
replication by binding to sites located in the viral genome (92).
Herpes simplex virus establishes latency in sensory neurons. Accordingly, herpes viral
lytic gene expression could be modulated by neuronal miRNAs, which can act to drive virus into
latency. This area has received minimal attention so far. The role of neuronal miRNAs in
establishing HSV latency was shown in a recent report by Pan et al. which demonstrated that
neuron specific miRNA, miR-138 repressed expression of ICP0, a viral transactivator of lytic
gene expression of HSV-1. This effect promoted viral latency (84). Another recent report by
O’Connor and colleagues demonstrated that miR-200, a miRNA enriched in the CD34+ myeloid
lineage targeted immediate early genes of human cytomegalovirus (hCMV) and promoted viral
latency in those cells (93). Thus, host miRNAs may have evolved to target viral genes and
thereby inhibit viral replication and represent a part of the host’s antiviral immune response.

Viral miRNAs regulating host and viral genes
More than 250 virus-encoded miRNAs have been discovered. However, detailed
understanding for most of them is in its infancy. Herpes viruses, adenovirus, and members of
polyomavirus family encode for miRNAs. Since all these viruses are DNA viruses, it reflects the
fact that they might use cellular Drosha and DGCR8 to process the pre-miRNA within the
nucleus. Most RNA viruses that replicate in the cytoplasm of the cell most likely do not encode
miRNAs since they do not have access to Drosha and DGCR8. Just like host miRNAs, which
are capable of regulating host and viral genes, viral miRNAs, can also target host and viral
mRNAs. This could establish a favorable environment in the host cell for virus replication or on
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the contrary make the cell less susceptible to viral replication. Evidence for both these scenarios
exists and is discussed below.

Viral miRNAs regulating host genes
Kaposis Sarcoma-associated Herpes virus (KSHV), EBV and hCMV are some of the herpes
virus family agents that encode miRNAs. These miRNAs are involved in modulating the lifespan
of infected cells, immune evasion and the regulation of latency. Accordingly, KSHV expresses at
least 18 different mature microRNAs, which it employs for various functions. KSHV miRNAs
(miR-K5, miR-K9, miR-K10) were shown to target BCLAF1 which is an apoptotic factor (94).
Blockade of miR-K5, miR-K9 or miR-K10 in latently infected cells attenuated virus production
even after reactivation signals, suggesting involvement of these miRNAs in stabilizing latency.
Also miR-K10 was shown to target TGF-β type- II receptor thereby inhibiting TGF-β signaling
(95). TGF-β was shown to be a tumor suppressor due to its growth-inhibitory effect and is also
known to be proapoptotic (96). Thus KSHV viral miRNAs can promote viral latency and
contribute to malignant cellular transformations by targeting host cellular proapoptotic factors.
Additionally, miR-K9 could target IRAK1 and miR-K5 targeted MYD88, both of which are
critical factors in TLR/IL-1R signaling pathways (97). Thus KSHV miR-K9 and K5 could
potentially suppress the innate immune response to make the environment favorable for its
replication. Not only could KSHV viral miRNAs employ methods to suppress the innate immune
response but KSHV miR-K1, miR-K3-3p, miR-K6-3p, and miR-K11, could also downregulate
thrombospondin 1 (THBS1) and help the virus to evade adaptive immunity (98). THBS1
functions as a chemoattractant and helps in recruitment of monocytes and T cells to sites of
infection (99). Thus dowregulation of THBS1 by KSHV viral miRNAs could help KSHV	
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infected cells avoid detection by host T cells. Lastly it was shown that KSHV has a viral miRNA
(miR-K12-11) that can function as an analog of the host miRNA miR-155 and targets similar
host genes as does miR-155 itself (100). It is well known that miR-155 is an oncogeneic miRNA
(reviewed in (101)). It could be possible that the miR-155 analog of KSHV could cause the cell
to become oncogenic.
Other viruses such as EBV also employ similar strategies. EBV viral miRNA (miRBART5) can target host cellular mRNA p53 upregulated modulator of apoptosis (PUMA), which
is a pro apoptotic factor (102). Additionally, another EBV viral miRNA (miR-BHRF1-3) was
shown to target CXCL11, which is a chemotractant for T cells (103). Thus it is conceivable that
downregulation of CXCL11 by the viral miRNA may allow infected cells to avoid T-cell
detection and killing.
hCMV also encodes for viral miRNAs and one viral miRNA (miR-UL112-1) targeted
MHC class I polypeptide-related sequence B (MICB) host cell mRNA (104, 105). MICB is
expressed by stressed cells, which is recognized by the NKG2D receptor on NK cells resulting in
NK cell activation and elimination of the MICB expressing target cells (104-106). Thus,
targeting of MICB by miR-UL112-1 could help hCMV to evade NK cell attack.

Viral miRNA regulating viral genes
Viral miRNAs not only target host genes but can also target viral mRNAs and facilitate
viral replication by inhibiting the ability of the host antiviral immune response to identify and
eliminate infected cells and also in its ability to establish latency.
The first report about viral miRNA regulating viral genes was described in EBV as viral
DNA polymerase was found to be a target of EBV-miR-BART2. Accordingly, forced expression
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of miR-BART2 lead to downregulation of BALF-5 and lesser amounts of virus released from
EBV-infected cells (107). This indicated that EBV-miR-BART2 inhibits transition from latent to
lytic viral replication.
Another virus that might utilize its own miRNAs to establish latency is HSV-1. HSV-1
establishes long term latent infection in neuron of the TG and can reactivate occasionally,
leading to localized productive viral replication and infection. HSV expresses the transcript
latency associated transcript (LAT) exclusively during latency and this transcript serves as the
primary miRNA precursor that encodes four different viral miRNAs of which miR-H2-3p and
miR-H6 were shown to influence latency in ex-vivo neuronal cultures (108). miR-H2-3p
regulated the expression of ICP0 while miR-H6 reduced the expression of ICP4. However, the
contribution of viral-encoded miRNAs in regulating HSV latency in vivo remains to be seen.
Another virus where viral miRNA might affect either establishment or maintenance of
latency is hCMV. Accordingly two reports have shown that hCMV miRNA miR-UL112-1 is
able to target the viral gene IE1 (109, 110). IE1 is an immediate-early gene product required for
activating transcription of hCMV early genes. Moreover, when miR-UL112-1 was prematurely
expressed early in hCMV infection, production of less virions was observed (110). It is still not
known whether miR-UL112-1 is expressed during latency; however it is speculated that this
miRNA could play a role in and results in reduced early viral gene expression at late times of
lytic infection thus resulting in increased viral latency.
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Figure 1.1 miRNA biogenesis
The generation of miRNAs involves nuclear and cytoplasmic processing steps. In the nucleus,
pri-miRNAs, transcribed by RNA polymerase from DNA, are processed by Drosha into premiRNAs that are then transported to cytoplasm via exportin 5. Once in the cytoplasm, these premiRNAs are recognized and cleaved by Dicer into 20 to 22 bp duplexes that enter RISC. In
RISC, the passenger strand is cleaved while the guide strand directs RISC machinery to target
mRNAs resulting in mRNA degradation or inhibition of protein translation.
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CRITICAL ROLE OF MIR-155 IN HERPES
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Abstract
Herpes simplex virus (HSV) infection of adult humans occasionally results in lifethreatening herpes simplex encephalitis (HSE) for reasons that remain to be defined. An animal
system that could prove useful to model HSE could be miR-155 knockout mice (miR-155KO).
Thus we observe that mice with a deficiency of miR-155 are highly susceptible to HSE with a
majority of animals (75-80%) developing HSE after ocular infection with HSV-1. The lesions
appeared to primarily represent the destructive consequences of viral replication and animals
could be protected from HSE by acyclovir treatment provided 4 days after ocular infection. The
miR-155KO animals were also more susceptible to develop zosteriform lesions, a reflection of
viral replication and dissemination within the nervous system. One explanation for the
heightened susceptibility to HSE and zosteriform lesions could be because miR-155KO animals
develop diminished CD8 T cell responses when the numbers, functionality and homing capacity
of effector CD8 T cell responses were compared. Indeed, adoptive transfer of HSV-immune CD8
T cells to infected miR-155KO mice at 24 hours post infection provided protection from HSE.
Deficiencies in CD8 T cell numbers and function also explained the observation that miR155KO animals were less able than control animals to maintain HSV latency. Our observations
may be the first to link miR-155 expression with increased susceptibility of the nervous system
to virus infection.

Introduction
Infections with herpes simplex virus (HSV) usually cause lesions at body surfaces such
as the skin, mucosal surface and the eye. Characteristically, after primary infection HSV
establishes a non-replicating persistent (latent) infection in neuronal tissue, which can break
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down periodically and give rise to recurrent lesions at primary lesion sites (1). A rare yet often
tragic manifestation of HSV infection is dissemination to the brain with resultant herpes simplex
encephalitis (HSE) (2). In adult humans HSE is usually caused by HSV-1 and can occur in
persons whom are seropositive and latently infected with virus (2). Additionally, infants can
develop encephalitis if seronegative and incur primary infection usually with HSV-2 (2). A rare
form of HSE also occurs in children with genetic defects in innate immune defenses (3-5). Once
virus enters the brain, the lesions that follow are considered to either be the consequence of viral
replication in critical cells (3, 6) and/or be caused by an inflammatory response to the infection
(7-9). Support for the latter ideas comes mainly from studies in rodents. For example, mild
lesions occur in gene knockout animals that lack the expression of some innate immune receptors
involved in causing inflammatory responses (7, 8). Further support for the inflammation
hypothesis came from studies showing that whereas antiviral therapy had no effect on disease
outcome inflammatory cell depletion markedly diminished HSE (9).Conceivably, the
pathogenesis of herpes encephalitis could differ in the natural host from that studied in animal
model systems.
MicroRNAs regulate gene expression post transcriptionally and are implicated in some
immunoinflammatory diseases in humans and in various mouse models of human diseases (10,
11). For example, animals deficient in miR-155 are relatively resistant to develop autoimmune
disease, such as EAE an animal model for the human disease multiple sclerosis (12, 13).
MicroRNA-155 also plays a critical role in the pathogenesis of human rheumatoid arthritis with
miR-155 being upregulated in the synovial membrane cells and assumed to function by
promoting inflammatory cytokine production (14, 15). Mouse studies have indicated that miR155 influences inflammatory disease by both promoting the expansion of pro-inflammatory Th1
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and Th17 cells as well as amplifying effects on inflammatory gene expression in macrophages
and T cells (12, 14).
Few studies have evaluated the role of miRNAs in the pathogenesis of virus infections. In
the present report, we have evaluated the susceptibility of animals with a deficiency for miR-155
because of gene knockout to ocular and intradermal infection with HSV-1. We demonstrate that
miR-155KO mice show heightened susceptibility to HSV ocular infection, with the majority of
animals succumbing to HSE under conditions where wild type (WT) animals remained normal.
miR-155KO mice were also markedly more susceptible than WT to develop zosteriform lesions
upon intradermal infection, a lesion that reflects viral dissemination into the nervous system (16).
Additionally, ganglionic latent infection with HSV-1 reactivated more abundantly from miR155KO than WT latently infected ganglia upon ex-vivo culture. One explanation for the
observations was that miR-155KO animals developed diminished virus specific CD8 T cell
responses, particularly those that were functionally effective. Other mechanistic explanations
were also discussed.

Materials and methods
Mice: Female 5-6wks old C57BL/6 mice were purchased from Harlan Sprague Dawley Inc.
(Indianapolis, Indiana, USA). Breeder pair’s of miR-155KO mice on C57BL/6 background were
obtained from Jackson laboratories (Bar Harbor, ME) and additional mice were bred in the
Walters Life Sciences animal facility at the University of Tennessee, Knoxville. HSV-specific
TCR transgenic mice (gBT-I.3- referred to in the text as gBT mice) were produced in the
laboratory of Francis Carbone (University of Melbourne, Melbourne, Australia). The animals
were housed in American Association of Laboratory Animal Care-approved facilities at the
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University of Tennessee, Knoxville. All investigations followed guidelines of the institutional
animal care and use committee.

Virus: Three different strains of virus were used. HSV-1 Tumpey (obtained from Dr. Robert
Lausch, University of South Alabama), HSV-1 RE (obtained from Dr. Robert Hendricks,
University of Pittsburgh) and HSV-1 KOS (obtained from Dr. David Knipe, Harvard University)
were used. All strains were propagated and titrated on monolayers of Vero cells (ATCC CCL81)
using standard protocols. All virus stocks were aliquoted and stored at -80°C.

Infection of mice: Infections of all mice groups (5-8 week old) were conducted under deep
anesthesia with avertin (Tribromoethanol). For corneal infection, the mice were scarified on their
corneas with a 27-gauge needle, and a 3 µl drop containing 104 PFU of HSV-1 Tumpey was
applied to one eye and was used to monitor the development of encephalitis. In experiments
involving HSV reactivation, mice were infected with 105 PFU of HSV-RE for corneal infection.
The zosterifrom infection was used in some of the experiments. The zosteriform infection was
performed as described earlier (16). Briefly, hair was clipped on each left flank and depilated
with Veet hair removal cream after anesthetizing the mice using avertin intraperitoneal injection.
A small area of skin (1cm2) near the top of the spleen was scarified with a 27 gauge needle, and
20 µl of HSV-1 Tumpey containing 106 PFU of virus was applied to hair-depleted area of the
skin and massaged. Additionally, in some experiments HSV footpad model was used. Mice were
injected subcutaneously in each hind footpad (FP) with 4x105 PFU HSV-1 KOS in 30µl of
phosphate-buffered saline (PBS). Mice were sacriﬁced at day 5 pi, and the PLN were isolated for
analysis.
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Adoptive transfer of HSV-immune CD8+ T cells
To generate HSV-immune CD8+ T cells, gBT mice were scarified on their corneas with a 27gauge needle, and a 3µl drop containing 104 PFU of HSV-1 Tumpey was applied to one eye.
Single-cell suspensions of pooled spleens and popliteal lymph nodes were prepared from
immunized mice 7–8 days later, and CD8+ T cells were purified using a mouse CD8 T cell
isolation kit from miltenyl biotec. By flow cytometry analysis, the purified population consisted
of 85% CD8+ T cells. Ocularly infected miR-155KO animals received an intra venous injection
of 20 × 106 purified cells at 24 hours pi.

Immunohistochemistry
Groups of miR-155KO mice and WT mice were ocularly infected with 106 PFU of HSV-1
Tumpey and mice showing signs of encephalitis from each group (day 8 pi) were anesthetized
with avertin and transcardially perfused with isotonic sucrose solution; sucrose perfusion was
followed by perfusion with a solution of 4% paraformaldehyde (PFA). Post fixation of the brain
samples were done by immersion of the skull in the same 4% PFA fixative for 1 day. After brain
extraction from the skull, cryoprotection was done in 10% glycerol on day 1 and 20% glycerol
on day 2. Mouse brains were embedded within a single gelatin matrix, freeze cut into 35µm
coronal sections, and collected into 24 series (Neuroscience Associates Knoxville, TN). Each
12th section was then stained as free-floating section. High-sensitivity immunohistochemistry on
multibrain sections was performed essentially following the protocol described by Osmand et al.
and Hoffman et al. (17, 18) This involved treatment with sodium borohydride, blocking with
0.5% Triton X-100, and overnight incubation in a solution of primary antibody at a
predetermined optimal concentration, followed by exposure to biotinylated species-specific
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secondary antibody and enzymatic detection using a 1:500 dilution of reagents A and B from the
ABC Elite reagent (Vector Laboratories) and Ni–DAB–glucose-glucose oxidase (19). Sections
were mounted and cover slipped without the use of counter stains.

Abs and reagents
APC-conjugated

anti-mouse

CD8a

(53-6.7),

FITC-conjugated

anti-mouse

TNF-α,

allophycocyanin-conjugated anti-mouse IFN-γ, FITC-conjugated anti-mouse CD49d, FITCconjugated anti-mouse CD44 and Golgi transport inhibitor (brefeldin A) were purchased from
BD

Biosciences.

Allophycocyanin-conjugated

and

PE-conjugated

H-2Kb/gB498–505

(SSIEFARL) tetramers were provided by the National Institutes of Health Tetramer Core Facility
(Emory University, Atlanta, GA). Recombinant mouse Gal-9 was provided by GalPharma,
Japan. CD8 T cell isolation kit was obtained from Miltenyi Biotec. Primary antibodies Rat AntiMouse CD8a and Rabbit Anti-Glial Fibrillary Acidic Protein (GFAP) for immunohistochmeistry
staining were purchased from BD Biosceince and DAKO respectively. The secondary antibodies
Donkey Anti-Rat IgG (H+L) and Donkey Anti Rabbit IgG (H+L) were purchased from Jackson
Immunoresearch.

Preparation of TG single-cell suspensions
At 14 days after HSV-1 RE ocular infection, mice were anaesthetized and euthanized by
exsanguinations (20). TGs were excised and subjected to collagenase type I treatment (SigmaAldrich, St. Louis, MO) at a concentration of 3 mg/ml for 90 min at 37°C. After incubation, the
TGs were dispersed into single cells by trituration. Each single cell suspension was then plated in
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48-well tissue culture plates. The cells were cultured in DMEM with 10% FCS and 10 U/ml
recombinant murine IL-2 (R&D Systems) as described (20).

Ex vivo reactivation experiments
Each TG sample isolated from miR155KO mice was divided into 2 aliquots. One aliquot was left
unmanipulated and the other aliquot received 1x105 CD8 T cells isolated at day 8 pi from lymph
nodes of HSV-1 infected WT mice. Similarly, each WT TG was divided into 2 aliquots and one
aliquot was left unmanipulated whereas, the other aliquot received 1µM rGal-9 a procedure
shown in a previous report to block CD8 T cell function and result in viral reactivation (21). TG
cultures were incubated in DMEM in a 5% CO2 humidified incubator at 37°C for a 10 day
period and culture supernatant samples were collected at 24-h intervals and assayed for
infectious virus by plaque titrations on Vero cells. Gal-9 (1µM) and IL-2 (10U/ml)
concentrations were constantly maintained throughout the culture period.

Flow Cytometry: Single-cell suspensions isolated from draining cervical lymph nodes, and TG
samples of mice ocularly infected with HSV-1 were collected at different time points.
Additionally in separate experiments were foot infection was used; PLN were isolated and made
into single cell suspensions after HSV-1 footpad infection. Aliquots of the above single-cell
suspensions were stained for CD8 and Kb-gB tetramer cell surface markers. To enumerate the
functionality of CD8 T cell, intracellular staining was performed with freshly isolated DLN, PLN
or TG suspensions from WT and miR-155KO mice. The cells were cultured in U-bottom 96-well
plates and left untreated or stimulated with gB498–505 (SSIEFARL) peptide (1 µg/ml) and
incubated for 6 h at 37°C in 5% CO2. Brefeldin A (5µg/ml) was added for the duration of the
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culture period to facilitate intracellular cytokine accumulation. After this period, cell surface
staining was performed, followed by intracellular cytokine staining using a Cytofix/Cytoperm kit
(BD Pharmingen) to enumerate the number of IFN-γ and TNF-α producing CD8 T cells as
previously described (22). Finally, the cells were washed three times and re-suspended in 1%
para-formaldehyde. The stained samples were acquired with a FACS Calibur (BD Biosciences)
and the data were analyzed using the FlowJo software.

Viral plaque assay: Virus titers were measured in the brain, TG and skin of HSV infected mice
as described previously by others (9, 21, 23). Additionally, mouse corneas were swabbed with
sterile swabs (Fisher HealthCare, USA) at 6 days after ocular infection. Virus titers in all
samples were measured using standard plaque assay as described previously (24).

Statistics: Mortality data were analyzed by log-rank testing (taking into account both time of
death and final mortality). The statistical significance between two groups was determined using
unpaired two-tailed student's t test. One-way ANOVA with Bonferroni’s post hoc test was used
to calculate the level of significance for some experiments. P ≤ 0.001 (***), P ≤ 0.01 (**), P ≤
0.05 (*) were considered as significant and results are expressed as mean ± SEM. For all
statistical analysis, GraphPad Prism software was used.

Results
Differential susceptibility of miR-155KO and WT mice to ocular infection with HSV
Upon ocular infection with HSV, mice develop a T cell orchestrated immnoinflammatory
lesion in the cornea (stromal keratitis (SK)) and susceptible strains may succumb to encephalitis
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(25, 26). The latter outcome has also been advocated to represent an immunoinflammatory
reaction to virus replication (8, 9). Since miR-155KO animals express higher resistance than WT
animals to the induction of some immunoinflammatory diseases (12, 13), we anticipated that
miR-155KO animals would be more refractory than WT animals to both SK and HSE. We did
observe significantly heightened resistance to SK (these data will be documented in a separate
manuscript), but unexpectedly miR-155KO animals were markedly more susceptible to HSE
than were the WT animals. Thus under infectious conditions with a strain of HSV-1 virus which
failed to cause detectable illness or symptoms of encephalitis in WT animals, 75-80% (in three
separate experiments) of miR-155KO animals developed encephalitis and most had to be
terminated by 9 days post infection (pi) (Figure 2.1A). By 6 days pi, affected animals became
lethargic, lost weight, showed ruffled fur, hunched appearance and signs of incoordination. To
cause encephalitis with the same virus strain in WT required a virus dose that was 1000 times
greater, and then fewer than 20% developed encephalitis. Brains were collected from
encephalitic miR-155KO animals, both to investigate pathological changes as well as to quantify
levels of virus present. High virus levels of HSV were detectable in brain homogenates in all
showing signs of encephalitis by day 9 pi, although none had detectable virus in ocular swabs at
day 6 pi (Figure 2.1B and C). Virus could not be detected in the brains at day 9 pi or in the ocular
tissue at day 6 pi in the WT animals when infected at the low virus dose that caused encephalitis
in the miR-155KO animals (Figure 1C).
Brain sections from miR-155KO and WT animals examined 8 days pi and showing signs
of encephalitis revealed differences in the nature of pathological changes. Thus the density of
CD8 T cell infiltration in the posterior temporal lobe was notably more abundant in the WT
animals than in the miR-155KO animals (Figure 2.2A). There was also marked differences in the
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extent of astrocytosis indicative of inflammatory reactions to infection with the response more
abundant in WT animals (Figure 2.2B).
The above observations are consistent with the viewpoint that the CNS damage in the
miR-155KO animals was likely the consequence of the direct effects of virus infection rather
than an immunopathological response to infection. Further support for this notion also came
from experiments, which showed that ocularly infected miR-155KO animals could be protected
from developing encephalitis if treated with acyclovir starting at 4 days pi (Figure 2.3A and B).
Moreover animals killed 5 days after treatment expressed minimal levels of virus in brain
extracts compared to untreated animals (Figure 2.3C). In separate experiments we could recover
infectious virus from the brains of both miR-155KO and WT mice one day before acyclovir
treatment. However, higher viral titers were evident at day 4 pi in the miR-155KO animals
(Figure 2.3D).
Our results are consistent with the notion that miR-155KO animals succumb to
encephalitis with lesions in the brains likely the direct consequence of viral infection rather than
representing the result of an inflammation reaction to infection, as some advocate accounts for
encephalitis in WT mice (9).

miR-155 is required for optimal CD8 T cell responses
To investigate whether or not miR-155 influences the nature of HSV-1 specific CD8 T
cell responses, miR-155KO and WT mice were infected intradermally in the hind footpads with
HSV-1 strain KOS and effector CD8 T cell responses were measured in the draining popliteal
lymph nodes (PLN) at day 5 pi when responses are at their peak (27, 28). The results show that
the total numbers of HSV gB tetramer specific CD8 T cells per lymph node were significantly
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reduced (~3 fold) in miR-155KO mice compared to WT control animals (Figure 2.4A). We also
investigated the homing capacity of CD8 T cells in the miR-155KO animals. Analyzing
expression of the homing molecules VLA-4 and CD44, we found ~1.5-3 fold reduced expression
in the infected miR-155KO animals compared to the WT animals (Figure 2.4B and C).
Additionally, no differences were evident in the expression of the homing molecule LFA-1
between the infected WT and miR-155KO animals (data not shown). When cell numbers were
compared using the intracellular cytokine staining (ICS) assay to detect virus specific IFN-γ
producing cells, differences between miR-155KO and WT responses were of even greater
magnitude (average of 5 fold) (Figure 2.4D). As an additional measure of functional responses,
numbers of CD8 T cells that produced both IFN-γ and TNF-α or a single cytokine alone were
compared in the two groups. This approach revealed that dual cytokine producing CD8 T cells
were reduced ~10 fold in miR-155KO compared to WT (Figure 2.4E), a result we take to
indicate that the CD8 virus specific response in miR-155KO mice was functionally impaired. In
additional experiments this trend was also seen in the DLN at day 9 after ocular infection with
the HSV-1 strain that caused encephalitis in miR-155KO mice (data not shown).
In separate experiments, WT and miR-155KO mice were infected with another strain of
HSV-1 (HSV-1 RE) that did not cause HSE in miR-155KO mice. In such experiments,
trigeminal ganglia (TG) were collected 14 days pi and processed either for viral reactivation
experiments (described in a subsequent section) or to recover T cells to measure virus specific
CD8 T cell responses by using both tetramer and the ICS assay to quantify cytokine producers.
The total numbers of gB tetramer specific CD8 T cells were ~2 fold higher in WT compared to
miR-155KO mice (Figure 2.5A). The number of total CD8 T cells that produced IFN-γ in the
WT group was ~4 fold higher compared with miR-155KO animals. Additionally, the dual
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cytokine (IFN-γ and TNF-α)-producing cells were ~4.5 fold more frequent in WT mice as
compared with miR-155KO mice (Figure 2.5B and C).
Taken together the above data demonstrate that the absence of miR155 results in
diminished CD8 T cell response, which is particularly evident when using assays that measure
numbers of functional CD8 T cells.

HSV-immune CD8+ T cells from gBT mice protect miR-155O animals from lethal herpetic
encephalitis
To see if the reduced number and function of CD8 T cells is one of the reasons for HSE,
we carried out adoptive transfer experiments. Infected miR-155KO mice were given HSVimmune CD8+ T cell transfers from gBT mice at 24h pi, and recipients were monitored clinically
over the next 9 days. 80% of the miR-155KO mice succumbed to death by day 9 pi, however
100% of the miR-155KO mice that received HSV-immune CD8 T cells at 24h pi survived
(Figure 2.6A). Animals were subsequently sacrificed at day 9 pi and brains were collected to
quantify levels of virus present. High virus levels were detectable in the brain homogenates in all
miR-155KO animals showing signs of encephalitis by day 9 pi, although none had detectable
virus in the group of animals that received CD8 T cell adoptive transfers (Figure 2.6B).

Virus reactivation differences between latently infected miR-155KO and WT mice
In additional experiments, WT and miR-155KO mice were infected with a strain of HSV1 (HSV-1RE) that did not cause HSE in KO mice. In such experiments TG were collected 14
days pi and processed to induce viral reactivation ex vivo (20, 21). In these experiments, multiple
TG cultures from individual miR-155KO and WT infected mice were established 14 days pi and
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aliquots were exposed to different treatments. The culture supernatants were tested daily to
detect infectious virus over a 10 day period. Unmanipulated cultures revealed differences in the
viral reactivation pattern between miR-155KO and WT TG. Whereas ~15% of WT cultures
showed reactivation, ~ 90% of the miR-155KO cultures reactivated (Figure 2.7). Infectious virus
was detectable in the miR-155KO culture supernatants by day 2 post culture but not until day 3
in the WT cultures that reactivated. Although the majority of WT cultures did not reactivate all
were judged to be latently infected since the addition of 1mM rGal-9 (a procedure shown
previously to cause ex-vivo reactivation (21)) caused virus reactivation in all cultures (Figure
2.7).
With the miR-155KO cultures CD8 T cells isolated from the lymph nodes of WT HSV
infected mice were added to culture aliquots to determine the effect on virus reactivation. This
procedure prevented virus reactivation in all cultures (Figure 2.7). Accordingly, our results
demonstrate that viral reactivation from latency occurs far more readily with cultures from miR155KO animals than WT and this observation might be attributed at least in part to differences in
CD8 T cell function.

Differential susceptibility of miR-155KO and WT mice to intradermal infection with HSV
Animals infected in the scarified skin with HSV develop so called zosteriform skin
lesions which as first demonstrated by Nash and colleagues, reflect the consequence of viral
entrance into sensory nerve endings followed by viral replication in the dorsal root ganglia and
subsequent spread to the dermatome (16). When groups of WT and mir-155KO were infected
intra-dermally with identical viral dosage of HSV, the outcome was significantly different in the
development of zosteriform lesions. Thus a greater proportion of miR-155KO mice developed
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lesions compared to WT mice. By day 6 pi, 100 % of the miR-155KO mice had developed
lesions compared to only 25 % in the WT mice. In addition, miR-155KO mice exhibited lesions
that were far larger in size than in those in WT that developed lesions (Figure 2.8A). In addition
whereas, by day 7 pi, the majority of the miR-155KO mice developed hind limb paralysis all of
the WT mice remained free from any neurological signs (Figure 2.8B). In some experiments, test
mice were terminated at day 6 pi and virus levels were assayed in the skin encompassing the
inoculation site as well as in the brain. In such experiments, it was only possible to detect virus in
the brains and skin isolated from miR-155KO animals (Figure 2.8C and D). Thus our results
demonstrate a marked increase in susceptibility of miR-155KO to HSV infection in a model that
reflects spread within the nervous system.

Discussion
Herpes simplex virus infection usually causes lesions at body surface sites but
occasionally the virus spreads to the brain inducing life threatening encephalitis (2). We show in
this report that mice unable to produce miR-155 may develop HSE following ocular infection
with the lesion primarily the direct consequence of virus replication in the CNS. Affected
animals could be protected from HSE by acyclovir treatment commenced 4 days after infection
and pathological features in the CNS were consistent with direct viral destructive effects. miR155KO animals were also more susceptible to develop zosteriform lesions, a reflection of viral
replication and dissemination within the nervous system. One explanation for the heightened
susceptibility to HSE and zosteriform lesions could be because miR-155KO animals develop
diminished CD8 T cell responses especially when the numbers of functional effector CD8 T cell
responses were compared. Indeed, adoptive transfer of HSV-immune CD8 T cells into infected
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miR-155KO mice provided protection from HSE. Deficiencies in CD8 T cell numbers, function
and homing capacity may also explain the observation that miR-155KO animals were less able
than WT animals to maintain latency upon ex-vivo culture. Our observations may be the first to
link miR-155 expression with susceptibility of the nervous system to virus infection.
HSE is a rare manifestation of HSV infection and can be a devastating disease especially
if not treated promptly (2). Most cases in adult humans are caused by HSV-1 and these usually
occur in latently infected persons whose previous clinical consequences of infection were either
not observed, or were only mild surface lesions. Little is understood regarding the triggers that
cause reactivated virus to traffic to the brain or the pathogenic mechanisms involved at causing
the brain damage. Occasional cases of human HSE can occur in children with genetic defects in
TLR3 dependent interferon responses (3-5), but in the great majority of HSE cases genetic
defects in immune function have not been demonstrated (2). Moreover, even profound
immunosuppression, as can occur during AIDS or immunosuppressive therapy, very rarely
results in HSE. In HSE in humans, encephalitis appears to be largely the consequence of virus
replicating in and destroying cells, an idea supported by the success that can be achieved using
antiviral drug therapy (2). However, others advocate that an inflammatory reaction to the brain
infection can also contribute or perhaps be mainly responsible for the encephalitis (9).
Enthusiasm for the later idea has mainly come from experimental studies in mice where innate
immune signaling dependent activation of PMN and macrophages and the production of
inflammatory mediators in response to HSV were shown necessary for the development of
fulminate lesions of encephalitis (7, 8). Other studies indicate that encephalitis in susceptible
mouse strains may represent an immunopathological response since it fails to respond to antiviral
therapy but is controllable by procedures that diminish inflammatory cells (9). More than likely,
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the pathogenesis of HSE involves multiple mechanisms with studies in mice not accurately
reflecting the pathogenesis of the natural human disease. We advocate, however that the miR155KO mice could represent a more appropriate model than other mouse systems to understand
the pathogenesis of human HSE and to evaluate novel therapies. Accordingly, the encephalitis in
miR-155KO animals appeared to represent primarily the consequences of viral replication
events. Thus the disease was readily controllable with antiviral therapy even when this was
begun 4 days pi, a time point when HSV was readily detectable in the brains of miR-155KO
animals and presumably could be inducing an inflammatory response. Immunohistochemical
analysis of brain lesions of miR-155KO animals revealed lesser T cell inflammatory infiltrates in
affected areas along with less reactive astrocytosis as compared to WT animals with encephalitis.
We interpret this to mean that the nature of lesions in miR-155KO animals are less
immunoinflammatory than those in the WT animals.
We suspect that one reason miR-155KO animals readily developed HSE was because of
their reduced virus specific T cell responses to infection. Another might relate to the role that
miR-155 could play in susceptibility of neural tissue to HSV infection (discussed subsequently).
It is well known that the CD8 T cell response plays a critical role in protecting both the CNS and
peripheral nervous tissues (PNS) from HSV infection (20, 29, 30). Particularly strong evidence
for the protective effects of CD8 T cells in the PNS has come from the Hendricks and Carbone
laboratories (20, 23, 31). In addition, our own past studies showed how CD8 T cells are needed
to protect the CNS (29). The present observations showed that miR-155KO mice had
significantly diminished virus specific CD8 T cell responses, especially when numbers of
functionally competent CD8 T cells were compared where differences could be as much as 10
fold. This is consistent with the recent observations made by other groups who noted
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compromised CD8 T cell responses in miR-155KO animals in response to LCMV and influenza
virus infection, as well as in some tumor models (32-35). Additionally, it is conceivable that
brain homing capacity of CD8 T cells differed between KO and WT animals. In support of this
we could show that KO CD8 T cells showed diminished levels of VLA-4 and CD44 both shown
in other systems to influence brain homing of T cells (36, 37). We suspect that the diminished
protective CD8 T cell response permitted virus to traffic effectively to the brain and PNS and
that once there fewer protective CD8 T cells were around to abort infection. This is consistent
with the previous reports showing that CD8 deficient animals failed to control HSV in the brain
and developed encephalitis (30). This argument was also supported by the adoptive transfer
experiments where HSV immune CD8 T cells adoptively transferred to miR-155KO mice were
shown to be fully protective. However further experiments are needed to clarify if the apparent
defect in miR-155KO CD8 T cells is a problem with priming, effector cytokine production,
homing defects or additional events such as the numbers of cells that can access the nervous
system. Furthermore although we favor the idea that differences in CD8 T cell activity accounted
for the difference in outcome in miR-155KO and WT mice other explanations merit exploration
such as differences in NK cell homeostasis or levels of interferon induced which have both been
implicated as providing protection in herpetic encephalitis (7, 38-40).
A diminished protective CD8 response in miR-155KO animals was also demonstrated
using two models that reflect the activity of CD8 T cells. First in a food pad infection model we
could show that miR-155KO animals generated lesser numbers of HSV specific CD8 T cells
than WT animals in draining lymph nodes which was especially evident when IFN-γ producing
cell responses were compared. CD8 T cells are required to contain HSV replication in ganglia
and they orchestrate this response largely by IFN-γ production and the release of granzyme B in
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HSV infected neurons (20, 41, 42). In studies reported herein, we could show that ganglionic
virus specific CD8 T cells were diminished and less polycytokine producers in miR-155KO
animals compared to WT which might account for their more rapid and abundant reactivation.
In addition to encephalitis we also observed that miR-155KO mice were more susceptible
than the WT animals to develop zosteriform lesions, an event that requires dissemination of virus
within the nervous system (16). Accordingly, with doses of virus that produced barely noticeable
lesions in WT, almost all miR-155KO animals developed overt lesions and many had to be killed
because of hind limb paralysis. The miR-155KO animals failed to control HSV and virus was
easily detectable in the brains of miR-155KO animals, but could not be demonstrated in the
brains of WT animals.
Currently it is not clear how miR-155 influences the magnitude and functionality of CD8
T cell responses, but there are several possibilities. Firstly it might result from the fact that miR155KO mice also generate impaired helper T cell responses (12, 13), and optimum CD8 T cell
responses are known to require signals from CD4 helper T cells (43, 44). It is also conceivable
that miR-155 plays a direct role during CD8 T cell differentiation. Thus some have observed that
in the absence of miR-155 type 1 interferon driven proliferative responses of CD8 T cell are
defective (33, 34) while others suggest that CD8 T cells survive less well and show defective
responses to PI3K/AKT signaling (34). It has also been suggested that in the absence of miR155, SOCS1 is upregulated which expresses suppressive effects on T cell function (32). Further
studies are clearly needed to clarify how miR-155 expression influences the CD8 T cell
response.
Our results also raise the issue as to whether miR-155 expression somehow influences the
dissemination of HSV to and replication within the nervous system. Thus miRNAs could
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influence expression of proteins involved in axon transport but this point has not been
investigated to our knowledge. Alternatively miRNAs could influence the infectivity and
replication efficiency in target cells within the nervous system. It is known for example that miR155 regulates microglia immune responses by targeting SOCS-1 and promoting cytokine and
nitric oxide production (45, 46). So it is conceivable that the glial cells in miR-155KO mice
could be defective in cytokine and nitric oxide production, a possibility we are currently
investigating. We are also investigating if different cell types taken from miR-155KO and WT
mice show differential susceptibility to HSV replication events.
In conclusion our report makes the novel observation that deficiency of a single species
of miRNA can result in enhanced susceptibility of the nervous system to a virus infection. Our
observations lead us to wonder if miRNA defects could be involved in some cases of human
HSE. Moreover, it is also curious to note that glucocorticoids which are upregulated during
stressful situations that cause herpes reactivation may selectively inhibit miR-155 expression (10,
47). Thus the relationship of miR-155 expression to changing events in HSV pathogenesis merits
further investigation.
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Figure 2.1 miR-155KO mice are highly susceptible to encephalitis after HSV-1 infection
and have elevated viral titers in the brain but no difference in the cornea
Groups of WT and miR-155KO (KO) animals were ocularly infected with 1x104 HSV-1
Tumpey. (A) Survival of age matched WT and miR-155 KO was established over 9 days. (B)
Brains were harvested from WT and miR-155 KO mice at day 9 pi. Brains were homogenized
and centrifuged, and supernatants were tested for virus titers. (C) The presence of virus in the
cornea was measured at day 6 pi by swabbing the HSV infected eye with a sterile swab and
assaying for the virus by plaque assay. The level of significance was determined by a Student t
test (unpaired). Error bars represent means ± SEM (n = 5–8 mice/group). Experiments were
repeated at least three times. *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.001.
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Figure 2.1
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Figure 2.2 Infiltration of CD8 T cells and astrocytosis by immunohistochemistry of HSVinfected WT and miR-155KO mice.
Brains were collected from WT and miR-155KO mice that showed signs of encephalitis after
ocular infection with 1x106 HSV-1 Tumpey at day 8 pi. Brains were embedded in gelatin and
sections were stained with different antibodies. (A) Posterior temporal lobe staining of naïve
(Left) infected WT (center) and infected miR-155KO (right) mice for CD8 T cells (black arrows)
(15.03 ± 4.713 arbitrary units, p≤ 0.05) (B) Striatum staining of naïve (left) and infected WT
(center) and infected miR-155KO (right) mice for astrocytes (39.10 ± 7.804 arbitrary units, p≤
0.005). The figure shows the pictures of the sections taken at 20X magnification. Bar = 50µ.
Statistical analysis was performed by gray scaling and inverting the images and then calculating
the staining intensities using Photoshop. Statistical significance was determined by a Student t
test (unpaired). (n = 3–4 mice/group).
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Figure 2.3 Viral replication in the brain is the cause of encephalitis in the miR-155 KO
mice.
(A) WT and miR-155KO mice ocularly infected with 104 PFU HSV-1 Tumpey were either given
1mg acyclovir or vehicle intraperitonealy (i.p.) daily starting day 4 pi until day 8 pi. (B) Survival
for all the groups of mice was established over a 9 day period. (C) Brains were harvested and
homogenized from these different groups of mice at day 9 pi and the supernatants were measured
for virus titer. (D) In separate experiments WT and miR-155KO mice were ocularly infected
with 104 PFU HSV-1 Tumpey and brains were harvested and homogenized at days 1,2,3 and 4 pi
and supernatants were measured for virus titer. Data are representative of three independent
experiments and show mean values ± SEM (n = 4-8mice/group). Statistical levels of significance
were analyzed by one-way ANOVA test with Tukeys post test settings. *p ≤ 0.05 , **p ≤ 0.005,
***p ≤ 0.001
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Figure 2.3
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Figure 2.4 miR-155 KO mice mount weaker CD8 T cell responses compared to WT mice
after HSV-1 footpad infection.
Groups of wild type (WT) and miR-155KO (KO) animals were infected in the hind footpads
with HSV-1 strain KOS. PLN were collected at day 5 pi and aliquots of single-cell suspensions
were stained for cell surface markers CD8 and Kb-gB tetramer (A) Representative FACS plots,
frequencies and numbers of tetramer specific CD8 T cells in WT versus miR-155KO mice. To
measure Kb-gB tetramer specific CD8 T cell responses aliquots of single cell suspension of
PLN’s were stimulated for 6 hours with HSV-1 gB peptide in the presence of brefeldin A. After
stimulation the cells were stained for the surface marker CD8 and cytokines IFN-γ and TNF-α.
(B) Representative FACS plots, frequencies and numbers depicting IFN-y producing CD8 T
cells and (C) IFN-γ and TNF-α double producing CD8 T cells in WT versus miR-155KO mice.
The level of significance was determined by a Student t test (unpaired). Error bars represent
means ± SEM (n = 3 – 5 mice/group). Experiments were repeated at least three times. *p ≤ 0.05,
**p ≤ 0.005, ***p ≤ 0.001.
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Figure 2.4
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Figure 2.5 miR155 KO mice mount impaired CD8+ T cell responses in TG compared with
WT mice.
Kb-gB tetramer-specific CD8 T cell responses in TG of HSV-1– ocularly infected mice were
compared among age- and gender-matched HSV-1 infected WT and miR155 KO animals on day
14 pi. TGs were excised and individual TGs (n=8) from WT and miR155 KO mice were
dispersed into single cell suspensions and stained for cell surface markers CD8 and Kb-gB
tetramer (A) Representative numbers of tetramer specific CD8+ T cells in WT versus miR155KO mice. To measure Kb-gB tetramer specific CD8+ T cell responses single cell suspension
of TG’s were stimulated for 6 hours with HSV-1 gb peptide in the presence of brefeldin A. After
incubation, the cells were stained for surface marker CD8 and cytokines IFN-γ and TNF-α by
ICS and analyzed by flow cytometry. (B) Representative FACS plots, frequencies and numbers
depicting IFN-γ producing CD8 T cells and (C) IFN-γ and TNF-α double producing CD8+ T
cells in WT versus miR-155KO mice. The level of significance was determined by a Student t
test (unpaired). Error bars represent means ± SEM (n = 3–5 mice/group). Experiments were
repeated at least three times. *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.001
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Figure 2.5
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Figure 2.6 Survival in miR-155KO mice after receiving HSV immune CD8 T cells
miR- 155KO (KO) animals were ocularly infected with 1x104 HSV-1 Tumpey and were divided
in two groups. One group (n=8) received adoptive transfer of HSV immune CD8+ T cells via tail
vein at 24 h pi (A) while other group served as a control. Survival of age matched miR-155ko
mice and miR-155 KO animals that received CD8 T cell adoptive transfer was established over 9
days. (B) Brains were harvested from mir-155KO animals and miR-155 KO mice that received
CD8 T cell adoptive transfer mice at day 9 pi. Brains were homogenized and centrifuged, and
supernatants were tested for virus levels.
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Figure 2.7 Comparison of ex vivo HSV-1 reactivation between miR155 KO and WT mice.
Individual TGs excised on day 14 pi from HSV-1 (RE) infected WT and miR155KO mice were
dispersed into single-cell suspensions and the cultures were established in a 48 well plate. Each
TG (n=6) sample from miR155 KO mice was divided into 2 aliquots. One aliquot was left
unmanipulated and the other aliquot received 1x105 CD8 T cells isolated at day 8 pi from lymph
nodes of HSV-1 infected WT mice. Similarly, each WT TG was divided into 2 aliquots and one
aliquot was left unmanipulated whereas, the other aliquot received 1mM rGal-9. TG cultures
were incubated in DMEM medium for a 10 day period and samples of culture supernatant were
collected at 24-h intervals and assayed for infectious virus by plaque titrations on Vero cells. Bar
graph represents the percentage of virus reactivation from various experimental combinations.
The experiment has been repeated 3 times.
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Figure 2.8 Zosteriform lesions are more severe in miR-155KO mice compared to WT mice
and miR-155KO mice show impaired viral clearance from both brain and skin.
A group of WT and miR-155KO mice was infected with 1x106 HSV-1 Tumpey using flank
scarification. (A) Mice were examined on day 6 pi for secondary lesion development. (B) Mice
were observed for lesion development for up to 7 days pi and scored as following: scores of 1 or
2: local site lesions, characterized by ulceration and swelling around the site of infection; Score
of 3: progression of vesicles and then ulcers (Score of 4 or 5) down the flank of the mouse; Score
of 6: significant morbidity, characterized by partial immobility (C) Brains were harvested from
WT and miR-155 KO mice at day 6 pi. Brains were homogenized and centrifuged, and
supernatants were tested for virus titers using plaque assay. (D) The primary site of skin
inoculation was examined for viral titers at day 6 pi using plaque assay. The level of significance
was determined by a Student t test (unpaired). Error bars represent means ± SEM (n=4–8
mice/group). Experiments were repeated at least three times. *p ≤ 0.05, **p ≤ 0.005, ***p ≤
0.001
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Figure 2.8
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Chapter 3
ROLE OF MIR-155 IN THE PATHOGENESIS OF
HERPES STROMAL KERATITIS
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Abstract
Ocular infection with herpes simplex virus 1 (HSV-1) can result in a chronic
immunoinflammatory lesion that is a significant cause of human blindness. A key to controlling
stromal keratitis (SK) lesion severity is to identify cellular and molecular events responsible for
tissue damage and manipulate them therapeutically. Potential targets for therapy are microRNAs
(miRNAs), but these have been minimally explored especially in responses to infection. In this
study, we demonstrated that miR-155 expression was upregulated after ocular HSV-1 infection,
with the increased miR-155 expression occurring mainly in macrophages and CD4+ T cells and
to a lesser extent in neutrophils. In vivo studies demonstrated that microRNA-155 knockout
(miR-155-/-) mice were more resistant to herpes SK with marked suppression of Th1 and Th17
cell responses both in the ocular lesions and the lymphoid organs. The reduced SK lesion
severity was reflected by increased phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1
(Ship1) and IFN-gamma receptor alpha-chain (IFN-γRα) levels in activated CD4+ T cells in the
lymph nodes. Finally, in vivo silencing of miR-155 by the provision of antagomir-155
nanoparticles to HSV-1 infected mice led to diminished SK lesions and corneal vascularization.
In conclusion, our results demonstrate that miR-155 contributes to the pathogenesis of SK and
represents a promising target to control SK severity.

Introduction
Ocular infection with herpes simplex virus 1 (HSV-1) can result in a chronic tissue damaging
response in the stroma, which is considered to be largely the consequence of a host inflammatory
response to the infection (1). This concept has been strongly supported by animal model studies
where lesions were shown to be mainly orchestrated by CD4+ T cells with neutrophils and
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macrophage largely responsible for the tissue damage (2-5). Several effective control measures
for stromal keratitis (SK) have been suggested (6). These include approaches that influence
cellular infiltration and activation of the proinflammatory mediators of SK (6). One potential
means of modulating SK lesions that so far has received minimal attention is to manipulate the
expression of microRNA (miRNA) species that affect either virus or host events during SK.
A prime miRNA candidate for consideration is miR-155 since this miRNA can influence
the expression of several immune events that contribute to tissue damage (7-10). For example,
animals unable to produce miR-155 because of gene knockout may develop milder lesions in
some models of autoimmunity, (8, 11-13) and suppressing miR-155 expression, as can be
achieved by treatment with antagomirs, holds promise as a means of therapy for autoimmunity
(13). However, the absence of miR-155 can result in higher susceptibility to some virus
infections as well as some tumors in part because protective CD8+ T cell responses are
diminished (14-17). In fact, overexpression of miRNA can result in enhanced CD8+ T cell
mediated immune protection with some tumors (17).
Few studies have focused on the role of miR-155 in situations where the immune
response to an infectious agent may be a principal cause of tissue damage. This is the situation in
ocular lesions of the cornea following HSV-1 infection. In the present study, we have compared
the disease outcome after HSV-1 infection in microRNA-155 knockout (miR-155-/-) animals as
well as in animals in which miR-155 was suppressed by antagomir therapy with controls. We
show that HSV-1 infection resulted in upregulation of miR-155, which was mainly produced by
the inflammatory cells and T cells in the cornea. Suppression of miR-155 production resulted in
milder lesions that were associated with diminished Th1 and Th17 responses as well as reduced
inflammatory cytokine production. We also demonstrated that miR-155 suppression resulted in
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increased phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 (Ship1) and IFN-gamma
receptor alpha-chain (IFN-γRα) levels, molecules known to be required for IFN-γ expression and
Th1 differentiation (17, 18). These results indicates that miR-155 regulates differentiation as well
as effector function of Th1 cells. Thus, our results suggest that miR-155 could be a promising
therapeutic target to treat SK.

Materials and Methods
Mice: Female 6-8-week-old C57 BL/6 mice were purchased from Harlan Sprague Dawley Inc.
(Indianapolis, IN). miR-155-/- mice on C57BL/6 background were obtained from Jackson
laboratories. The animals were housed in American Association of Laboratory Animal Careapproved facilities at the University of Tennessee, Knoxville. All investigations followed
guidelines of the institutional animal care and use committee.

Virus
HSV-1 strain RE Tumpey was propagated in Vero cell monolayers (American Type Culture
Collection [ATCC], Manassas, VA; no: CCL81). Virus was grown in Vero cell monolayers,
titrated, and stored in aliquots at –80˚C until used. Ultraviolet (UV) inactivation of the wild-type
HSV virus (1.5 x 105 PFU) was carried out for 8 minutes.

Corneal HSV-1 infection and scoring
Corneal infections of mice were performed under deep anesthesia. The mice were lightly
scarified on their corneas with a 27-gauge needle, and a 3 µL drop containing 104 PFU of HSV-1
RE was applied to one eye. Mock-infected animals were used as controls. These mice were
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monitored for the development of SK lesions. The SK lesion severity and angiogenesis in the
eyes of mice were examined by slit-lamp biomicroscopy (Kowa Company, Nagoya, Japan). The
scoring system was as follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal
opacity or scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and corneal
ulcer; and +5, corneal rupture and necrotizing keratitis (19). The severity of angiogenesis was
recorded as described previously (20). According to this system, a grade of 4 for a given
quadrant of the circle represents a centripetal growth of 1.5 mm toward the corneal center. The
score of the four quadrants of the eye were then summed to derive the neovessel index (range 0–
16) for each eye at a given time point.

Subconjunctival injections
Subconjunctival injections were performed as previously reported (21). Briefly, these injections
were performed using a 2-cm, 32-gauge needle and syringe (Hamilton, Reno, NV) to penetrate
the perivascular region of conjunctiva, and 1µg scrambled sequences/antagomir-155
nanoparticles was administered into the subconjunctival space.

Antagomir sequences
Antagomir-155 and scrambled sequences were procured from Ambion (Austin, TX) and used as
previously reported (22).

Nanoparticle preparation
Optimized histidine-lysine polymers have been applied for small-interfering RNA deliveries in
vitro and in vivo (23). One HK polymer species, H3K4b, having a lysine backbone with four
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branches containing multiple repeats of histidine and lysine, was used for packaging smallinterfering RNAs against miR-155 or scrambled sequences, with a nanoparticle to sequence ratio
of 4:1 by mass. The nanoparticles (average size, 150 nm diameter) were self-assembled, and
these histidine-lysine polymers-small-interfering RNA nanoparticles were used in mice.

Murine treatment with antagomir-155 nanoparticles
Mice ocularly infected with HSV-1 RE Tumpey were separated into two groups. Antagomir-155
nanoparticle treatment was begun at day 1, with additional doses on alternate days until day 13
after infection. In another group of experiments, the antagomir-155 treatment was started at day
5, with additional doses every day until day 13 after infection. The control group received
nanoparticles containing scrambled sequences subconjunctively with the same regimen for
respective experiments. These animals were carefully followed for the progression of
angiogenesis and SK development.

Administration of intravenous immunoglobulins (IVIG)
IVIG (Carimmune, NF) was obtained from Gammagard Liquid. Wild type (WT) and miR-155-/mice were intraperitonealy (ip) injected with IVIG (3.75 mg/mouse) at day 4 post-infection (pi).
The dose of IVIG was chosen to be 3.75mg/mouse based on previous studies (24).

Flow Cytometry
Single cell suspensions from cornea, cervical draining lymph nodes (DLN), and spleen of mice
ocularly infected with HSV-1 were collected at day 15 pi. Aliquots of the above single-cell
suspensions were stained for CD4, CD45, CD11b, and Ly6G cell surface markers. In apoptosis
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studies, single cell suspensions of DLN were stained for Annexin V using a kit from BD
Biosciences. Additionally, cells were also co-stained for CD4, CD44, and viability (Live/Dead
fixable dead cell staining kit from Invitrogen). To enumerate the functionality of CD4+ T cell,
intracellular staining was performed. Briefly, 106 cells freshly isolated from DLN and spleens or
the entire corneal samples were left untreated or stimulated with phorbol 12-myristate 13-acetate
(PMA) plus ionomycin along with Golgi plug and incubated for 4 hours at 37°C in 5% CO2.
After this period, cell surface staining was performed, followed by intracellular cytokine staining
using a Cytofix/Cytoperm kit (BD Pharmingen) to enumerate the number of IFN-γ and IL-17A
producing CD4+ T cells as previously described (25). Finally, the cells were washed twice and
re-suspended in 1% para-formaldehyde. For intracellular staining of Ki-67 (BD Bioscience),
cells were fixed and permeabilized using the FoxP3 Staining Buffer Set (eBioscience) according
to the manufacturer’s recommendations. All the stained samples were acquired with a FACS
LSR (BD Biosciences) and the data were analyzed using the FlowJo software. For DLN and
spleen samples approximately 200,000 events were recorded. For corneal samples depending on
the number of corneas pooled approximately 300,000 to 1.5 × 106 events were recorded.

Purification of macrophages, CD4+ T cells, and neutrophils
Briefly, the excised corneas were pooled and digested with 60 U/mL Liberase for 35 minutes at
37°C in a humidified atmosphere of 5% CO2. A single-cell suspension was prepared and stained
with different combinations of the following antibodies anti-CD4 APC, anti-CD45 Percp, antiCD11b PE, anti- Ly6G FITC or F4/80 FITC for 30 minutes on ice. Approximately 50,000120,000 CD4+ T cells, macrophages (CD45+, CD11b+, F4/80+), and neutrophils (CD45+,
CD11b+, Ly6G+) were sorted using a fluorescence-activated cell sorter (FACS). The expression
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of miR-155 was measured on these sorted cells. In separate experiments, lymph nodes from
HSV-1 infected WT and miR-155KO animals were collected at day 15 pi. A single-cell
suspension was prepared and stained with different combinations of the following antibodies
anti-CD4 APC, anti-CD44 FITC, and anti-CD62L PE for 30 minutes on ice. 2.5 × 105 naïve
CD4+ T cells (CD4+ CD62Lhi CD44lo) and activated CD4+ T cells (CD4+ CD62Llo CD44hi)
were FACS sorted. Purity to an extent of 80-90% was achieved. The expression of miR-155,
Ship1 and IFN-γRα were measured on these sorted cells.

Quantification of mRNA and miRNA expression levels by quantitative real time PCR (QRTPCR)
Total mRNA and miRNA was isolated from corneal and lymph node cells using mirVana
miRNA Isolation Kit (Ambion). For RNA, cDNA was made with 500 ng RNA using oligo (dT)
primer and ImProm-II™ Reverse Transcription System (Promega). For miRNA, cDNA was
made with 5ng of miRNA using the taqMan microRNA reverse transcription kit (Applied
Biosystems) and primers for miR-155 and small nucleolar RNA 202 (SnoRNA202). TaqMan
microRNA Assays (miR-155 and SnoRNA202) and taqman gene expression assays (IL-6, IL-1β,
IL-17A, IFN-γ, CCL-2 and CXCL-1, Ship1, and IFN-γRα) were purchased from Applied
Biosystems and were used to quantify microRNAs and mRNAs using a 7500 Fast Real-Time
PCR System (Applied Biosystems). The expression levels of the target genes were normalized to
β-actin for mRNA and SnoRNA202 for miRNA with the ΔCT method, and relative
quantification between control and infected mice was performed using the (2-ΔΔCT) *1000
formula.
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Statistics:
Statistical significance for SK lesion severity and angiogenesis between the two groups was
determined using unpaired two-tailed student's t test. One-way ANOVA with Tukey’s multiple
comparison tests was used to calculate the level of significance for some experiments, where
noted in the results. P ≤ 0.001 (***), P ≤ 0.01 (**), P ≤ 0.05 (*) were considered as significant
and results are expressed as mean ± SEM. For all statistical analysis, GraphPad Prism software
was used.

Results
miR-155 Was Upregulated in Murine Corneas after Ocular Infection with Herpes Simplex
Virus
To investigate the potential role of miR-155 in mediating tissue damage during SK, mice
were ocularly infected with HSV-1 and miRNAs levels were quantified by Q-RTPCR in pools of
corneal extracts at various times pi. The results showed that miR-155 expression was upregulated
by day 2 pi (approximately 10 fold when compared to uninfected corneas) and increased with
progression of diseases at day 7 and 14 pi (approximately 20 fold when compared to uninfected
corneas) (Figure 3.1A). To demonstrate if replicating virus was required to upregulate miR-155
in eyes, mice were infected with live WT/UV-inactivated HSV and miR-155 expression was
analyzed. Our results show that UV inactivated virus upregulated the miR-155 equivalent to live
WT virus indicating that replicating virus is not required for miR-155 induction in eyes (Figure
S3.1). To further determine the cellular source of SK induced miR-155; neutrophils,
macrophages, and CD4+ T cells were purified from WT HSV-1 infected corneas at day 15 pi,
and miRNA extracts were tested by Q-RTPCR. CD4+ T cells taken from the lymph node of
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miR-155-/- mice served as a negative control for these experiments. Data showed miR-155
expression in neutrophils, macrophages and CD4+ T cells with the highest expression being
observed in CD4+ T cells and macrophages (Figure 3.1B). Collectively, these data demonstrated
that miR-155 expression was elevated at multiple time points after ocular HSV-1 infection and
that macrophages and CD4+ T cells were the major source of the miR-155 during the clinical
phase of the lesions.

miR-155-/- Mice Showed Defective CD4+ T Cell Responses and Reduced SK Lesion
Severity
To further study the role of miR-155 in SK pathogenesis, the outcome of HSV-1
infection was compared in WT animals and mice lacking miR-155 because of gene knockout.
Because HSV-1 infected miR-155-/- mice usually develop lethal herpetic encephalitis, (26)
infected mice were given a source of anti-HSV antibody (human IVIG) 4 days after infection,
which protects them against encephalitis, but does not interfere in the WT animals with the
extent of SK lesion severity. As shown in Figure 3.2A, animals in all groups were infected, but
levels of SK disease severity and the extent of angiogenesis were significantly diminished in the
miR-155-/- animals. The administration of IVIG had no effect on the severity of lesions in the
WT animals (Figure 3.2A). Further documentation of reduced severity in miR-155-/- animals
could be shown by histological evaluation (Figure 3.2B), as well as by quantifying the extent of
the inflammatory cellular events in sub pools of corneas taken from WT and miR-155-/- animals
at day 15 pi. As shown in Figure 3.2 C and D, the frequencies and numbers of total CD4+ T
cells, Th1 cells, and Th17 cells in the pooled corneal samples were decreased 5-6 fold in the
miR-155-/- mice compared with those in the WT mice. Additionally, analysis of DLNs and
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spleens of WT and miR-155-/- mice showed 2-3 fold reduced frequencies and total cell numbers
of each population (Figure 3.3 A and B). Taken together the results demonstrate that the
inflammatory response set off by ocular infection with HSV-1 was markedly decreased in mice
unable to express miR-155.

miR-155 Promoted CD4+ T Cell Proliferation after HSV-1 Infection
Prior studies have shown that miR-155 targets several pathways involved in survival and
proliferation of effector T cells (16, 27). We determined if proliferation or apoptosis could
account for the reduced number of effector T cells in miR-155 deficient animals. WT and miR155-/- mice were ocularly infected with HSV-1 and treated with IVIG at day 4 pi as described
above. Mice were sacrificed on day 14 pi and proliferation and apoptosis were detected by Ki67
and Annexin V staining respectively. Our results reveal that miR-155-/- CD4+ T cells show
significantly reduced proliferative response both in the DLN as well as in the cornea (Figure 3.4
A and B). However no differences were found in Annexin V+ CD4+ CD44hi cells in the DLN of
WT and miR-155-/- mice (Figure 3.4C). Thus, our data suggest that reduced numbers of Th1
and Th17 responses seen in miR-155-/- mice could be a due to defective proliferation of CD4+ T
cells both in the DLN and the cornea.

Provision of Antagomir-155 Nanoparticles Diminished SK lesion severity
To evaluate the effect of locally inhibiting miR-155 expression on the extent of stromal
keratitis, animals were subconjunctively given antagomir-155, or control scrambled sequence
nanoparticles, with treatment starting on either day 1 (preclinical phase) or day 5 (early clinical
phase) pi (Figure 3.5A and Figure S3.2A respectively). As shown in Figure 3.5B, treatment
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begun on day 1 resulted in significantly reduced SK scores in the antagomir-155 treated animals
and angiogenesis was also significantly reduced. Furthermore, histopathological analysis on day
14 pi showed that corneas from control scramble sequence treated mice were inflamed and
contained a massive infiltrate of inflammatory cells compared with antagomir-155 treated mice
(Figure 3.5C). An examination of sub pools of collagen-digested corneas at the termination of
experiments on day 14 revealed that the number and frequencies of inflammatory cells (CD4+ T
cells and neutrophils) were significantly diminished in the antagomir-155–treated group
compared to the control scramble sequence treated group (Figure 3.5D).
In the experiments in which treatment was begun in the early clinical phase on day 5 pi
when replicating virus is mostly cleared from the HSV-1-infected corneas, SK and angiogenesis
scores were also significantly diminished in the antagomir-155–treated animals (Figure S3.2B).
Additionally, histopathological analysis showed decreased cellular infiltration and inflammation
in the cornea in the antagomir-155–treated group compared to the scramble sequence treated
control group (Figure S3.2C). At the end of experiments on day 14, sub pools of corneal collagen
digests were analyzed by flow cytometry to enumerate the numbers and frequencies of CD4+ T
cells and neutrophils (Figure S3.2D). Both cell populations were significantly reduced in
frequency and number in the recipients of antagomir-155 compared with those that received the
scramble sequence control nanoparticles. Taken together, our results demonstrated that the
silencing of miR-155 at both preclinical and early clinical stages after HSV-1 infection
diminished pathological lesions and leukocyte infiltration.
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Antagomir-155 Nanoparticles Treatment Reduced Proinflammatory Cytokine and
Chemokine Levels in the Corneas of HSV-1 Infected Animals
To assess the effect of antagomir-155 treatment on proinflammatory cytokine and
chemokine production in SK, mRNA was prepared from corneal extracts on day 14 pi following
treatment that was started on day 1 pi. As shown in Figure 3.6A, samples from animals treated
with antagomir-155 showed a 7-8-fold reduction of proinflammatory cytokines IL-1β and IL-6
and a 3-4 fold reduction of IFN-γ and IL-17A when compared to scrambled sequence control
treated animals. Additionally, levels of chemokines involved in neutrophil (CXCL-1) and
monocyte (CCL-2) migration were significantly decreased in antagmoir-155 treated animals
(Figure 3.6B). These data indicate that the provision of antagomir-155 to HSV–1 infected mice
resulted in marked reduction of pro-inflammatory cytokines and chemokines.

miR-155 Targets Ship1 and IFN-γRα were Downregulated in Activated CD4+ T Cells
Observations in non-viral systems had indicated that miR-155 might influence several
immune events (7-10). Since CD4+ T cells of mainly the Th1 phenotype primarily orchestrate
SK, we chose to evaluate the Ship1 and IFN-γRα response since these are involved in regulating
IFN-γ expression and Th1 differentiation respectively (2, 17, 18). Experiments were performed
to measure the effects of miR-155 on levels of Ship1 and IFN-γRα in naïve and activated CD4+
T cells. Accordingly, WT and miR-155-/- mice were ocularly infected with HSV-1. At day 15 pi,
naïve CD4+ T cells (CD4+ CD62Lhi CD44lo) and activated CD4+ T cells (CD4+ CD62Llo
CD44hi) were FACS sorted from the lymph nodes and levels of miR-155, Ship1, and IFN-γRα
were quantified. As expected, there was a minimal level of miR-155 in naïve CD4+ T cells, but
activated CD4+ T cells showed an approximate, 20 fold upregulation (Figure 3.7A). The mRNA
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levels of Ship1 and IFN-γRα were elevated in the activated CD4+ T cells of miR-155-/- mice
compared to the WT mice, but no differences were observed in naïve CD4+ T cells among WT
and miR-155-/- mice (Figure 3.7 B and C). Collectively, these results indicated that miR-155
was upregulated in activated CD4+ T cells, which correlated with low Ship1 and IFN-γRα
mRNA levels in those T cells.

Discussion
In this report, we describe the influence of miR-155 on the expression of ocular lesions
caused by infection with HSV-1. The expression of miR-155 was shown to contribute to lesion
development, as animals unable to produce miR-155 because of gene knockout show
significantly reduced severity of stromal keratitis. That miR-155 was associated with the
development of SK lesions could also be shown by administration of miR-155 antagomirs in WT
animals early after infection, or around the time when lesions start to develop. Such animals had
suppressed SK lesions. Cells in SK lesions that were the main producers of miR-155 were CD4+
T cells and macrophages. The effect of miR-155 in lesion development was associated with
down regulation of Ship1 and IFN-γRα, genes involved in IFN-γ expression and Th1
differentiation respectively (17, 18). Increased miR-155 levels led to heightened production of
pro-inflammatory cytokines and chemokines and generation of pathogenic Th1 and Th17 cells in
the eyes during SK. Additionally we could see that miR-155 null CD4+ T cells showed impaired
proliferation following HSV-1 infection. These overall results were summarized in Figure 3.8.
The finding that a normal miR-155 response is needed to generate consequential SK lesions
implies that modulation of the expression levels could be a useful therapeutic strategy to limit the
severity of viral induced inflammatory lesions.
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Our study focused on miR-155 since this molecule was known to be involved in immune
and inflammatory reactions, (7-10) yet its role during viral infections had received minimal
investigation. Two reports showed that miR-155 influenced the magnitude of CD8+ T cell
responses to a virus infection (15, 28) and another showed that diminished miR-155 responses
led to more severe virus induced lesions in nervous tissue with animals more susceptible to
encephalitis (26). This latter outcome was at least in part the consequence of diminished CD8+ T
cell responses known to participate in protection of the central nervous system against HSV
infection (26). The present report evaluates the impact of miR-155 expression on the
inflammatory consequences of a virus infection, which in the model investigated occurs because
of an inflammatory process orchestrated by CD4+ T cells (1, 2). Our results clearly showed that
when miR-155 expression was suppressed, either because of gene knockout or the
administration of miR-155 specific antagomirs, lesions of SK were markedly reduced. In fact,
our results reflect observations made in some mouse models of autoimmune inflammation where
lesions were less evident in situations when miR-155 expression was limited (8, 12, 13). In
addition, some human auto-inflammatory lesions appear to be influenced by the magnitude of the
miR-155 response (9, 29). In our viral immunoinflammatory model, the major effect of miR-155
suppression was a significantly reduced CD4+ Th1 T cell reaction along with diminished non
antigen specific inflammatory cell infiltration into the cornea, with the latter cells mainly
responsible for tissue damage (3, 5). These effects were apparently the consequence of miR-155
affecting the levels of Ship1 as well as IFN-γRα in activated CD4+ T cells both of which were
significantly elevated when miR-155 expression was inhibited. Ship1 is a phosphatase that
negatively regulates cytokine signaling via repression of the PI3K pathway, (30) and its deletion
from CD4+ T cells results in elevated IFN-γ expression (31). Thus in our system since activated
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CD4+ T cells in miR-155KO mice showed higher levels of Ship1, it is likely that these cells
would have lower IFN-γ expression as has been shown in other models (17). Additionally, lower
IFN-γ expression could also be explained by defective differentiation of Th1 cells in miR155KO mice. Regulation of IFN-γ signaling through the IFN-γR is necessary for the
differentiation of Th1 cells (18, 32-34). miR-155, by targeting IFN-γRα mRNA might
downregulate the IFNγ receptor in activated CD4+ T cells that differentiate into Th1 cells (18).
We also observed much higher levels of IFN-γRα in the activated CD4+ T cells suggesting
defective Th1 differentiation in the miR-155-/- mice. The observed phenotype of reduction in
Th1 and Th17 cell numbers could also be explained by impaired proliferation and/or survival of
responding T cells. Our data supports reduced proliferation of miR-155-/- CD4+ T cells rather
than reduced survival based on the use of markers to indicate such effects.
As shown in some other systems, miR-155 could also degrade additional crucial targets
such as suppressor of cytokine signaling 1 (SOCS1) that negatively regulates T cell function.(35)
T cell specific deletion of SOCS1 results in multi-organ inflammatory lesions, which are
correlated with high levels of IFN-γ (35). We measured and compared the expression of SOCS1
in activated CD4+ T cells from WT and miR-155-/- mice but observed no significant differences
between the two (data not shown), suggesting that Ship1 and IFN-γRα were the major targets of
miR-155 in our study. miR-155 was also shown in in vitro cultures of CD4+ T cells to influence
IL-10 production with a higher fraction of miR-155-/- CD4+ T cells producing IL-10 (36).
However in the SK situation we failed to observe enhanced IL-10 production in the corneas of
either miR-155-/- or antagomir-155 treated mice (data not shown). Nevertheless, we observed
significantly reduced numbers of Th17 cells in HSV infected miR-155-/- mice. This is consistent
with the previous reports that show the role of miR-155 in Th17 cell differentiation (8, 37, 38).
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Targets other than Ship1 and IFN-γRα could be subject to modulation by miR-155 and this issue
is under further investigation.
It was interesting to observe that soon after HSV ocular infection, levels of miR-155 were
increased in corneal tissue. The stimulus for this early expression would likely not be the direct
result of viral infection of epithelial cells but would more likely represent the innate immune
stimulating activity of the virus. This was supported by our data showing UV-inactivated virus
could trigger miR-155 upregulation at day 2 pi. Thus HSV-1 is known to express at least three
Toll-like receptor (TLR) ligand activities, (39-41) and others have documented that TLR
stimulation can be a potent agonist for miR-155 production (10). Some herpes viruses do
themselves express several miRNAs but homologues of miR-155 are not one of them. In the case
of HSV-1, the miRNAs expressed by the virus are mainly involved in decisions between
productive and latent cycles of replication (42). In the clinical phase of SK, virus is no longer
present in the cornea, and at this time we could show that the major producers of miR-155
were proinflammatory T cells along with non-specific inflammatory cells, especially
macrophages. Macrophages form a minor cell population infiltrating corneas during SK. Some
reports suggest that macrophages have antiviral activity, which helps in clearing the virus from
the cornea (43). While other studies show that macrophages are in involved in the development
of immunologically driven stromal keratitis (5).
The stimulus for miR-155 production was not identified, but was most likely to include
either TLR ligand activity of the virus or cytokines such as IFN-β, IFN-γ, and TNF-α that are
present during SK and which were shown in other systems to act as miR-155 agonists (10).
Additionally, miR-155 also signals innate cells, such as neutrophils and macrophages, to produce
pro-inflammatory cytokines and chemokines (9, 10, 44). In cystic fibrosis patients, for example
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increased miR-155 expression in neutrophils led to increased neutrophil recruitment via IL-8
activity (9). It was also reported that miR-155 mediated degradation of BCL-6 in macrophages
leads to attenuation of NF-kB signaling resulting in diminished production of pro-inflammatory
cytokines and chemokines (44). Conversely, miR-155 induced repression of SOCS1 in
macrophages enhanced type I IFN signaling (45). In a collagen induced arthritis model, miR155-/- animals exhibited very low levels of inflammatory mediators in joints.11 miR-155 null
mice were also seen to be resistant to bacterial keratitis an effect mediated by miR-155 activity
on macrophages (46). In agreement with these observations, we could show in our study that
diminished miR-155 activity led to a dampened pro-inflammatory milieu in the eyes. Therefore,
the SK resistance phenotype observed in miR-155-/- animals is likely the consequence of
multiple events such as poor neutrophil and macrophage activity, dampened pro-inflammatory
milieu and attenuated Th1 and Th17 cell responses. This activity of miR-155 could make it a
viable therapeutic target to treat HSV induced ocular lesions.
One major rationale for research on miRNAs is the prospect that manipulating their
levels could represent a viable new approach to therapy. In fact accumulating evidence indicates
that the miRNA environment changes in the course of an inflammatory response with the
miRNA species present in the proinflammatory phase differing from those prominent during the
resolution phase of an inflammatory response (47, 48). It is still not clear if miRNAs are
primarily responsible for this switch of events but evidence is accumulating to support the
concept (48). In such a scenario, miR-155 may act as a facilitator of the resolution phase of an
inflammatory reaction. In support of this, we could show that the use of an antagomir to miR-155
at the early clinical phase diminished the severity of lesions. It seems likely that in a disease
situation, manipulating the expression of multiple miRNA species that are involved in different
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aspect of pathogenesis might be the most fruitful approach to therapy. In favor of this idea, in
our preliminary results we have observed that manipulating miR-155 along with miR-132, a
miRNA involved in angiogenesis, (22) may provide more therapeutic value than using either
miRNA alone. Current ongoing research is evaluating the value of manipulating the levels of
multiple miRNA in an attempt to achieve a more effective resolution of ocular inflammatory
reactions.
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Figure 3.1 Expression of miR-155 after HSV-1 infection.
(A) WT mice were infected with HSV-1 RE, and corneas were collected and pooled for miRNA
analysis by Q-RTPCR to measure the expression of miR-155 at days 2, 7 and 15 after HSV-1
infection. The expression levels of miR-155 were normalized to SnoRNA202 using the ΔCt
calculation. Relative expression was calculated using the 2−ΔΔCt formula. miRNA-155 levels in
mock-infected mice were set to 1 and used for relative fold upregulation. Data are representative
of three independent experiments and show mean values ± SEM (n = 9 mice per group; each
sample is representative of three corneas). (B) miR-155 expression was measured by Q-RTPCR
in sorted neutrophils, macrophages and CD4+ T cells from WT infected corneas at day 15 pi.
CD4+ T cells were isolated from the lymph nodes of miR-155-/- mice at day 15 after HSV-1
infection and served as a negative control. The expression levels of miR-155 were normalized to
SnoRNA202 using the ΔCt calculation. Relative expression was calculated using the 2−ΔΔCt
formula. Data are representative of two independent experiments and show mean values ± SEM
(n = 15 mice). Statistical significance was calculated by one-way ANOVA with Tukey’s multiple
comparison tests. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 3.1
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Figure 3.2 miR-155-/- mice were resistant to SK.
C57BL/6 and miR-155-/- mice ocularly infected with 1× 104 PFU of HSV-1 RE were
divided into three groups of eight to twelve mice. One group of WT mice received IVIG
intraperitonealy at day 4 pi (WT D4 IVIG). One group of miR-155-/- mice received IVIG at day
4 pi (miR-155-/- D4 IVIG) and one group of WT mice received no treatment (WT no IVIG).
Disease severity and immune parameters were evaluated at day 15 pi (A) SK lesion severity and
angiogenesis at day 15 pi are shown. A one-way ANOVA, with Tukey’s multiple comparison
tests, was used to calculate the level of significance. . *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. This
experiments was repeated three times. (B) Representative H&E-stained corneal sections (× 40
magnification) from WT (WT D4 IVIG) and miR-155-/- (miR-155-/- D4 IVIG) mice collected
on day 15 pi. (C-D) Mice were sacrificed on day 15 pi, and corneas were harvested and pooled
group wise for the analysis of various cell types (n = 8–12 per group). (C) Representative FACS
plots for corneal infiltrating total CD4+ T cells. Intracellular staining was conducted to quantify
Th1 and Th17 cells by stimulating them with PMA/ionomycin (D) Representative plots show
percentage of CD4+ cells producing IFN-γ or IL-17 following stimulation with PMA/ionomycin
in the cornea of infected WT (WT D4 IVIG) and miR-155-/- (miR-155-/- D4 IVIG) animals.
Plots shown were gated on CD4+ T cells. The bar graph represents total numbers of corneal
infiltrating CD4+ T cells, Th1 and Th17 cells in the corneas of WT (WT D4 IVIG) and miR-155/- (miR-155-/- D4 IVIG) mice. Data are representative of three independent experiments and
show mean values ± SEM (n = 8–12 mice per group). Statistical significance was analyzed by
the Student t test (unpaired). **p ≤ 0.01, ***p ≤ 0.001.
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Figure 3.3 miR-155-/- mice exhibited reduced frequencies and numbers of Th1 and Th17
cells in DLN and spleen post HSV-1 infection.
C57BL/6 and miR-155-/- mice were ocularly infected with 1× 104 PFU of HSV-1 RE. Both
groups of mice received IVIG intraperitonealy at day 4 pi. Mice were sacrificed on day 14 pi and
single cell suspensions of the individual spleen and DLN were prepared. (A) Representative
FACS plots show percentage of CD4+ T cells producing IFN-γ or IL-17A following stimulation
with PMA/ionomycin in the infected animals from the DLN and spleen. Plots shown were gated
on CD4+ T cells. (B) The bar graph represents total numbers of CD4+ T cells, Th1, and Th17
cells in the DLN and spleen of WT (WT D4 IVIG) and miR-155-/- (miR-155-/- D4 IVIG) mice.
Data are representative of three independent experiments and show mean values ± SEM (n = 5–6
mice per group). Statistical significance was analyzed by the Student t test (unpaired). *p ≤ 0.05,
***p ≤ 0.001.

	
  

100	
  

Figure 3.3
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Figure 3.4 miR-155-/- CD4+ T cells showed defective proliferation but not survival.
C57BL/6 and miR-155-/- mice were ocularly infected with 1× 104 PFU of HSV-1 RE. Both
groups of mice received IVIG intraperitonealy at day 4 pi. Mice were sacrificed on day 14 pi and
single cell suspensions of the individual DLN and sub pools of corneas were prepared and
stained for Ki67 and Annexin V. (A) Representative FACS plots, frequencies and cell numbers
of Ki67+ CD4+ T cells in the cornea of WT (WT D4 IVIG) and miR-155-/- (miR-155-/- D4
IVIG) mice are shown. Plots shown were gated on CD4+ T cells. (B) Representative FACS
plots, frequencies and cell numbers of Ki67+ CD4+ T cells in the DLN of WT (WT D4 IVIG)
and miR-155-/- (miR-155-/- D4 IVIG) mice are shown. Plots shown were gated on CD4+ T
cells. (C) Representative FACS plots and frequencies of Annexin V+ CD4+ CD44hi T cells in
the DLN of WT (WT D4 IVIG) and miR-155-/- (miR-155-/- D4 IVIG) mice are shown. Plots
shown were gated on live CD44hi CD4+ T cells. Data are representative of two independent
experiments and show mean values ± SEM (n = 6–8 mice per group). Statistical significance was
analyzed by the Student t test (unpaired). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 3.4
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Figure 3.5 Preventive administration of antagomir-155 diminished SK lesion severity and
cellular infiltration.
C57BL/6 mice were ocularly infected with 1× 104 PFU of HSV-1 RE. (A) Antagomir155/scrambled

sequence

(scrambled

seq)

(5'-AUUUCAUGACUGUUACUGACCU-3')

nanoparticle treatment was given subconjunctively as shown. Disease severity and immune
parameters were analyzed at day 14 pi. (B) SK lesion severity and angiogenesis at day 14 are
shown. (C) Representative H&E stained corneal sections (× 40 magnification) of scrambled seq
treated (left) and antagomir-155 treated (right) mice were collected on day 14 pi. Mice were
sacrificed on day 14 pi, and corneas were harvested and pooled group wise for analysis of
various cell types. (D) The frequency and total cell number of CD4+ T cells and neutrophils
(CD45+ CD11b+ Ly6G+) (plot was gated on CD45+ cells) infiltrated in the corneas of control
(scrambled sequence) (left panel) and antagomir-155 (right panel) treated mice are shown. Data
are representative of two independent experiments and show mean values ± SEM (n = 8–12 mice
per group). Statistical significance was analyzed by the Student t test (unpaired). ***p ≤ 0.001.
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Figure 3.5
	
  

105	
  

Figure 3.6 Antagomir-155 treatment reduced cytokine and chemokine levels in corneas of
HSV-1 infected animals.
C57BL/6 mice were ocularly infected with 1× 104 PFU of HSV-1 RE. The antagomir155/scrambled sequence (scrambled seq) nanoparticle treatment was given subconjunctively
every other day starting day 1 pi. Mice were sacrificed on day 14 pi, and corneal extracts were
collected for measuring inflammatory factors, using Q-RTPCR. (A) Relative fold change in
mRNA expression of the proinflammatory cytokines IL-6, IL-1β, IFN-γ and IL-17A was
examined and compared between control (scrambeled sequence) and antagomir-155 treated mice
on day 14 pi (B) Relative fold change in mRNA expression of chemokines CCL-2 and CXCL-1
was examined and compared between control (scrambled sequence) and antagomir-155 treated
mice on day 14 pi. The expression levels of different cytokines and chemokines were normalized
to β-actin using the ΔCt calculation. Relative expression was calculated using the 2−ΔΔCt formula.
mRNA levels for the different cytokines and chemokines in mock-infected mice were set to 1
and used for relative fold upregulation. Data are representative of two independent experiments
and show mean values ± SEM (n = 12 mice per group; each sample is representative of four
corneas). Statistical significance was analyzed by the Student t test (unpaired). *p ≤ 0.05, **p ≤
0.01.
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Figure 3.6
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Figure 3.7 Increased expression of Ship1 and IFN-γRα in miR-155-/- activated CD4+ T
cells.
C57BL/6 and miR-155-/- mice ocularly infected with 1× 104 PFU of HSV-1 RE. Both groups of
mice received IVIG intraperitonealy at day 4 pi. Mice were sacrificed on day 14 pi and single
cell suspensions of the individual cervical DLN were stained for CD4+, CD44 and CD62L. Cells
were then FACS sorted as CD4+ CD44hi CD62Llo (activated) and CD4+ CD44lo CD62Lhi
(naïve) from both the HSV-1 infected WT (WT D4 IVIG) and miR-155-/- (miR-155-/- D4 IVIG)
mice at day 14 pi. (A) miR-155 expression by Q-RTPCR in sorted naïve and activated cells.
Expression levels of miR-155 were normalized to SnoRNA202 using the ΔCt calculation.
Relative expression was calculated using the 2−ΔΔCt formula. (B) Expression of Ship1 mRNA in
sorted naïve and activated cells by Q-RTPCR. (C) Expression of IFN-γRα in sorted naïve and
activated cells by Q-RTPCR. Expression levels of Ship1 and IFN- γRα were normalized to βactin using the ΔCt calculation. Relative expression was calculated using the 2−ΔΔCt formula.
Data are representative of two independent experiments and show mean values ± SEM (n = 5–6
mice per group). Statistical significance was calculated by one-way ANOVA with Tukey’s
multiple comparison tests. *p ≤ 0.05, **p ≤ 0.01.
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Figure 3.7
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Figure 3.8 Illustration of miR-155 induced regulation of inflammatory response during
HSV-1 infection.
Left panel: Outcome (SK) in HSV-1-infected WT (miR-155 +/+) mice. HSV-1 infection leads
to ocular infiltration of Th1 and Th17 cells, the major orchestrators of SK. miR-155 degrades
IFN-γRα, Ship1, and conceivably other targets that cause increased numbers of these cells, along
with their heightened effector function. This increased proinflammatory response leads to severe
stromal keratitis. Right panel: Outcome (SK) in HSV-1-infected miR-155 -/- mice. HSV-1
infection of miR-155-/- mice leads to higher levels of IFN-γRα and Ship1 resulting in reduced
numbers and functionality of Th1 and Th17 cells. This results in attenuation of SK lesions.
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Figure 3.8
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Figure S3.1 UV inactivated HSV-1 virus upregulates miR-155.
C57BL/6 mice were ocularly infected with 1× 104 PFU of live HSV-1 or UV-inactivated HSV-1
virus. At day 2 after infection, animals were sacrificed, and corneas were collected and pooled
for miRNA analysis to measure the expression of miR-155. The expression levels of miR-155
were normalized to SnoRNA202 using the ΔCt calculation. Relative expression was calculated
using the 2−ΔΔCt formula. miRNA-155 levels in mock-infected mice were set to 1 and used for the
relative fold upregulation. Data are representative of two independent experiments and show
mean values ± SEM. Statistical significance was analyzed by the Student t test (unpaired).
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Figure S3.2 Therapeutic administration of antagomir-155 diminishes SK lesion severity
and cellular infiltrates.
C57BL/6 mice were ocularly infected with 1× 104 PFU of HSV-1 RE. (A) The antagomir155/scrambled seq nanoparticle treatment was given subconjunctively as shown. Disease
severity and immune parameters were analyzed at day 14 pi. (B) SK lesion severity and
angiogenesis at day 14 are shown. (C) Representative H&E stained corneal sections (× 40
magnification) of scrambled seq treated (left) and antagomir-155 treated (right) mice collected
on day 14 pi. Mice were sacrificed on day 14 pi, and corneas were harvested and pooled group
wise for the analysis of various cell types. (D) The frequency and total cell number of CD4+ T
cells and neutrophils (CD45+ CD11b+ Ly6G+) (plot was gated on CD45+ cells) infiltrated in the
corneas of control (scrambled sequence) (left panel) and antagomir-155 (right panel) treated
mice are shown. Data are representative of two independent experiments and show mean values
± SEM (n = 8–12 mice per group). Statistical significance was analyzed by the Student t test
(unpaired). *p ≤ 0.05, ***p ≤ 0.001.
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Chapter 4
CONCLUSION AND FUTURE PERSPECTIVES
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Herpes simplex virus infection generally leads to lesions on oral surface. In rare instances,
virus causes ocular lesions (herpetic stromal keratitis) or infection of the central nervous system
(herpes simplex encephalitis). Little is known about the involvement of miRNAs in the
pathogenesis of herpetic stromal keratitis and/or herpes simplex encephalitis. In our study we
focused on miR-155 involvement in both the diseases.
When miR-155 expression was analyzed after ocular HSV infection, we found
significantly higher levels in eyes at different time points. miR-155 plays critical role in
immunity as well as in inflammation. Thus, we set out to characterize the role of miR-155 after
HSV infection. In my first report I established that microRNA-155 knockout (miR-155KO) mice
are highly susceptible to HSE following ocular inoculation; mice were also more susceptible to
the development of zosteriform lesions following viral replication and dissemination within the
central nervous system. Additionally, the miR-155KO mice were unable to maintain HSV-1
latency. All theses phenotypes could be in part explained by defective CD8 T cell responses in
the miR-155KO animals. Future experiments will need to be done to evaluate the different
targets of miR-155 in CD8 T cells, which make them defective. Additionally, while evidence
suggested defective CD8 T cell responses contributed to the heightened susceptibility of the
miR-155KO mice to HSE, a role of CNS elements in influencing the dissemination and
replication of HSV within the brain under differential control of miR-155 could not be
eliminated. This area is currently being investigated in our lab.
In my second report I demonstrated that microRNA-155KO mice were also more
resistant to herpes SK with marked suppression of Th1 and Th17 cell responses both in the
ocular lesions and the lymphoid organs. The reduced SK lesion severity was reflected by
increased phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 (Ship1) and IFN-gamma
	
  
116	
  

receptor alpha-chain (IFN-γRα) levels in activated CD4+ T cells which could explain defective
Th1 cell responses. Future experiments would need to be done to investigate different targets of
miR-155 that lead to defective th17 responses. Finally, in vivo silencing of miR-155 by the
provision of antagomir-155 nanoparticles to HSV-1 infected mice led to diminished SK lesions
and corneal vascularization.
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